    		                		            		                                                                                                                                          	    		   		   	  	       	            							    	    																																			    																	    	    	                             		       	                                                                                                   	        						    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               									    	    																																			    																	    	    	                             		       	                                                                                               	            			        	                            						    	    																																			    																	    	    	                             		       	                                                                                                                                                                                                                   	     <!DOCTYPE html><html><head>        	<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />    <meta charset="utf-8" />        	<title>DailyMed - PRISTIQ EXTENDED-RELEASE- desvenlafaxine succinate tablet, extended release  </title>                <!--[if lt IE 9]>        <script src="//html5shim.googlecode.com/svn/trunk/html5.js"></script>    <![endif]-->    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/skeleton.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/jquery.jqzoom.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/style.min.css" />    <link rel="stylesheet" type="text/css" media="screen" href="dailymed/css/header-search.min.css" />    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive.min.css" />    <link rel="stylesheet" type="text/css" media="print" href="dailymed/css/print.min.css" />    <!--[if !IE]><!-->    <link rel="stylesheet" type="text/css" media="all" href="dailymed/css/responsive-tables.min.css" />    <!--<![endif]-->    <link rel="icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon" />    <link rel="shortcut icon" href="dailymed/images/favicons/favicon.ico" type="image/x-icon"/>        <link rel="apple-touch-icon" sizes="57x57" href="dailymed/images/favicons/apple-touch-icon-57x57.png">    <link rel="apple-touch-icon" sizes="114x114" href="dailymed/images/favicons/apple-touch-icon-114x114.png">    <link rel="apple-touch-icon" sizes="72x72" href="dailymed/images/favicons/apple-touch-icon-72x72.png">    <link rel="apple-touch-icon" sizes="144x144" href="dailymed/images/favicons/apple-touch-icon-144x144.png">    <link rel="apple-touch-icon" sizes="60x60" href="dailymed/images/favicons/apple-touch-icon-60x60.png">    <link rel="apple-touch-icon" sizes="120x120" href="dailymed/images/favicons/apple-touch-icon-120x120.png">    <link rel="apple-touch-icon" sizes="76x76" href="dailymed/images/favicons/apple-touch-icon-76x76.png">    <link rel="apple-touch-icon" sizes="152x152" href="dailymed/images/favicons/apple-touch-icon-152x152.png">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-196x196.png" sizes="196x196">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-160x160.png" sizes="160x160">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-96x96.png" sizes="96x96">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-16x16.png" sizes="16x16">    <link rel="icon" type="image/png" href="dailymed/images/favicons/favicon-32x32.png" sizes="32x32">    <meta name="msapplication-config" content="/dailymed/images/favicons/browserconfig.xml" />    <meta name="msapplication-TileColor" content="#da532c">    <meta name="msapplication-TileImage" content="/dailymed/images/favicons/mstile-144x144.png">    <meta name="description" content="" />    <meta name="keywords" content="" />     <meta name="robots" content="noimageindex, noodp, noydir" />     <meta name="viewport" id="viewport" content="width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0" />    <script src="/dailymed/scripts/modernizr-2.0.6.min.js"></script>        <script type="text/javascript" src="//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>        <script type="text/javascript">        if (typeof jQuery == 'undefined')        {              document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');        }    </script>                	                	            	    	<script type="text/javascript">		var basepath = "/dailymed";;		var availableClasses =  new Array();;		for(var i = 0; i < availableClasses.length; i++){			availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();		}		var labeltitle = "PRISTIQ EXTENDED-RELEASE- desvenlafaxine succinate tablet, extended release <br>";;		var emailLink = "";;		var emailrequest = "0";;	</script>    <script src="/dailymed/scripts/javascript-html-attribute-encoding.min.js"></script>	<script src="/dailymed/scripts/scripts.min.js"></script>        <script type='text/javascript' src="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js"></script>    <script type="text/javascript">        if (typeof jQuery.ui == 'undefined')        {            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="dailymed/css/jquery-ui-1.10.4.custom.min.css">');        }        else{            document.write('<link rel="stylesheet" href="/ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');        }    </script>    <script type='text/javascript' src='/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'></script>      <script type="text/javascript" src="/dailymed/scripts/jquery.placeholder.min.js"></script>    <script src="//www.accessdata.fda.gov/spl/stylesheet/spl.js" type="text/javascript" charset="utf-8">/* */</script>    <!-- Magnific Popup core CSS file -->    <link rel="stylesheet" href="dailymed/css/magnific-popup.min.css">        <!-- Magnific Popup core JS file -->    <script src="/dailymed/scripts/jquery.magnific-popup.js"></script>        <meta name = "format-detection" content = "telephone=no"></head><body class="inner drug-info">	<div class="container_1000 bg_shadow">        <div style="width: 0; height: 0;"><a href="#" id="top-of-page"></a></div><header>	<div class="topHeader">				<ul id="skip">		<li><a href="#skip-main-content">Skip to Main Content</a></li></ul>		<nav class="topHeaderNav">        	<div class="topNIHLogo mobileview">        		<a href="http://www.nih.gov" class="top-logo" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>            	<a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>			<div class="container">				<div class="sixteen columns">                	<div class="topNIHLogo"><a href="http://www.nih.gov" title="National Institutes of Health" target="_blank"><img src="/dailymed/images/nih-toplogo.png" alt="NIH Logo"/></a>                    <a href="/www.nlm.nih.gov" title="U.S. National Library of Medicine" target="_blank">U.S. National Library of Medicine</a></div>					<ul>																		<li class="safety"><a title="Report Adverse Events" href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events </a><span>|</span><a title="FDA Safety Reporting and Recalls" href="http://www.fda.gov/Safety/Recalls" target="_blank">Recalls</a></li>					</ul>				</div>			</div>		</nav>		<div class="divider"></div>	</div>	<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png" alt="DailyMed" /></div>	<div class="bottomHeader">		<div class="header-image">						<div class="mobile-menu-btn closed hasjs" tabindex="0"></div><div class="mobile-menu">		<div class="mobile-menu-container">		<div class="pro-menu active">			<div class="first half">				<ul>					<li><a href="dailymed/index.cfm">Home</a></li>					<li>						News						<ul>							<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>							<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>						</ul>					</li>					<li><a href="dailymed/about-dailymed.cfm">About Dailymed</a></li>					<li><a href="dailymed/contact-us.cfm">Contact Us</a></li>					<li>						Safety Reporting &amp; Recalls						<ul>							<li><a href="/www.accessdata.fda.gov/scripts/medwatch/">Report Adverse Events</a></li>							<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey Recalls</a></li>						</ul>					</li>					<li>						<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>											</li>				</ul>			</div>			<div class="last half">				<ul>					<li>						NLM SPL Resources						<ul>							<li>								<a href="dailymed/spl-resources.cfm">Download Data</a>								<ul>									<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>									<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>									<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>								</ul>							</li>							<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>							<li><a href="dailymed/spl-resources-all-mapping-files.cfm">Articles &amp; Presentations</a></li>						</ul>					</li>					<li>						Application Development Support						<ul>							<li>								<a href="dailymed/app-support.cfm">Resources</a>								<ul>									<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																		<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>								</ul>							</li>						</ul>					</li>					<li><a href="dailymed/help.cfm">Help</a></li>				</ul>			</div>		</div>			</div></div>			<a href="dailymed/index.cfm" class="logo" title="DailyMed">DailyMed</a>						<div class="header-search-container">				<div id="header-search">									    					    				    <form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all" value="all" />					<label for="labeltype-all">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human" value="human"/>					<label for="labeltype-human">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden" name="labeltype" id="labeltype-animal" value="animal" />					<label for="labeltype-animal">Animal Drugs</label>							</li>							<li class="more-ways" id="header-search-more-ways">					<a href="#" id="more-ways-button" class="more-ways-label">More ways to search</a>					<ul id="more-ways-dropdown" class="dropdown" style="display:none;">						<li>							<a href="dailymed/advanced-search.cfm">Advanced Search</a>						</li>						<li>							<a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a>						</li>						<li>							<a href="dailymed/archives/index.cfm">Label Archives</a>						</li>						<li>							<a class="external-link" href="http://pillbox.nlm.nih.gov" target="_blank">Tablet/Capsule ID Tool</a>						</li>					</ul>				</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">									<button class="search-button">  </button>							</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>									</div>			</div>			<div class="mobile-search-btn" tabindex="0"></div>												<div class="header-bg">																										</div>			<div class="divider"></div>		</div>		<div class="bottomHeaderContent">									<div class="search mobile-search">				<div class="divider_10 nomargin mobileview"></div>				<div class="searchTool mobileview"></div>															<form action="/dailymed/search.cfm">		<div class="searchNav">		<ul class="searchType">			<li class="all active">									<input type="radio" class="hidden" name="labeltype" id="labeltype-all-2" value="all" />					<label for="labeltype-all-2">All Drugs</label>							</li>			<li class="human">									<input type="radio" class="hidden" name="labeltype" id="labeltype-human-2" value="human"/>					<label for="labeltype-human-2">Human Drugs</label>							</li>			<li class="animal">									<input type="radio" class="hidden"  name="labeltype" id="labeltype-animal-2" value="animal" />					<label for="labeltype-animal-2">Animal Drugs</label>							</li>								</ul>	</div>			<div class="searchForm">					<div class="searchInput">				<input id="searchToolsQuery" name="query" tabindex="0" type="text" placeholder="Enter drug, NDC code, drug class, or Set ID" autocorrect="off" autocapitalize="off">			</div>								<input class="search" tabindex="0" title="Search" type="submit" value="Search">	</div></form>								<div class="divider"></div>								<nav class="bottomHeaderNav">                <noscript>                <div class="tabletnav no-js">                    <div class="col">                        <ul>                            <li><a href="dailymed/index.cfm">Home</a></li>                            <li>News                                <ul>                                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                                    <li><a href="dailymed/rss-updates.cfm">Get RSS News & Updates</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Search                                <ul>                                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>                                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                                        <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                            <li>NLM SPL Resources                                <ul>                                    <li><a href="dailymed/spl-resources.cfm">Download Data</a>                                        <ul>                                            <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                            <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                            <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                                        </ul>                                    </li>                                    <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                                    <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                                </ul>                            </li>                        </ul>                    </div>                                    <div class="col">                        <ul>                            <li>Application Development Support                                <ul>                                    <li><a href="dailymed/app-support.cfm">Resources</a>                                        <ul>                                            <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                            <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                                        </ul>                                    </li>                                </ul>                            </li>                            <li><a href="dailymed/help.cfm">Help</a></li>                        </ul>                    </div>                </div>           		</noscript>                					<ul class="webview hasjs">						<li><a href="dailymed/index.cfm" title="Home">Home</a></li>						<li>													<a href="#" title="News">												News</a>							<ul class="sub-menu">								<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>								<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>							</ul>						</li>						<li>																				<a href="dailymed/fda-drug-guidance.cfm" title="FDA Guidances &amp; Info">												FDA Guidances &amp; Info</a>													</li>						<li>													<a href="#" title="Structured Product Labeling (SPL) resources for industry professionals.">												NLM SPL Resources</a>														<ul class="sub-menu">								<li><a href="dailymed/spl-resources.cfm">Download Data</a>									<ul>										<li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>										<li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Indexing Files</a></li>										<li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>									</ul>								</li>								<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>								<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>							</ul>						</li>						<li>													<a href="#" title="Application Development Support">												Application Development Support</a>							<ul class="sub-menu">								<li><a href="dailymed/app-support.cfm">Resources</a>									<ul>										<li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>																				<li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>									</ul>								</li>							</ul>						</li>									  						<li>													<a href="dailymed/help.cfm" title="Help">												Help</a></li>   					</ul>					<ul class="tabletview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li><span>News</span>									<ul>										<li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>										<li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>									</ul>								</li>								<li><span>Safety Reporting and Recalls</span>									<ul>										<li><a href="/www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report Adverse Events</a></li>										<li><a href="/www.fda.gov/Safety/Recalls" target="_blank">FDA Saftey Recalls</a></li>									</ul>								</li>								<li>									<a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a>								</li>																<li><span>NLM SPL Resources</span>									<ul>										<li><a href="dailymed/spl-resources.cfm">Download Data</a>											<ul>												<li><a href="dailymed/spl-resources-all-drug-labels.cfm">- All Drug Labels</a></li>												<li><a href="dailymed/spl-resources-all-indexing-files.cfm">- All Indexing Files</a></li>												<li><a href="dailymed/spl-resources-all-mapping-files.cfm">- All Mapping Files</a></li>											</ul>										</li>										<li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>										<li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>									</ul>								</li>   								<li><span>Application Development Support</span>									<ul>										<li><a href="dailymed/app-support.cfm">Resources</a>											<ul>												<li><a href="dailymed/app-support-web-services.cfm">- Web Services</a></li>																								<li><a href="dailymed/app-support-mapping-files.cfm">- Mapping Files</a></li>											</ul>										</li>									</ul>								</li>   								<li><a href="dailymed/help.cfm" title="Help">Help</a></li>   							</ul>						</li>						<li class="mobileview viewmore" tabindex="0"><a title="View More" href="#">More ways to search</a>							<ul>								<li tabindex="0"><a title="Browse Drug Classes" href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>								<li tabindex="0"><a title="Label Archives" href="dailymed/archives/index.cfm">Label Archives</a></li>																<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool" href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>										<ul class="mobileview hasjs">						<li><a href="dailymed/advanced-search.cfm" title="Advanced Search">Advanced Search</a></li>						<li tabindex="0" class="viewmore"><a href="#" title="View More">View More</a>							<ul>								<li tabindex="0"><a href="dailymed/browse-drug-classes.cfm" title="Browse Drug Classes">Browse Drug Classes</a></li>								<li tabindex="0"><a href="dailymed/archives/index.cfm" title="Label Archives">Label Archives</a></li>																<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title="Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID Tool</a></li>   							</ul>						</li>					</ul>				</nav>				<div class="divider_10 nomargin"></div>			</div>					</div>				<div class="divider"></div>	</div></header><div id="skip-main-content"></div>        <div class="container">             <div class="main-content">                <div class="header long">                    <div class="header-top">                            <h1>Label: <span class="long-title">PRISTIQ EXTENDED-RELEASE- desvenlafaxine succinate tablet, extended release <br></span></h1>                    </div>                                        <ul class="tools">                    	                        <li class="rss"><a href="#modal-label-rss" class="modal-open">Label RSS</a></li>                        <li class="share">Share                            <noscript>: JavaScript needed for Sharing tools</noscript>                            <!-- AddThis Button BEGIN -->                            <div class="addthis_toolbox addthis_default_style addthis_16x16_style">                                                                                                    	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0APRISTIQ%20EXTENDED%2DRELEASE%2D%20Desvenlafaxine%20Succinate%20Tablet%2C%20Extended%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Da9ff32c4%2D3bcf%2D4e51%2Dae8c%2D81ff0191ec35%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                                <a class="addthis_button_facebook"></a>                                <a class="addthis_button_twitter"></a>                                                                <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="display: block;">                                    <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span><img style="width:17px" src="/dailymed/images/addthis-image.jpg"></img>                                </a>                            </div>                            <script type="text/javascript">var addthis_config = {"data_track_addressbar":false};</script>                            <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5" ></script>                             <!-- AddThis Button END -->                                                    </li>                    </ul>                  </div>                <div class="four columns sidebar" id="leftmenu">                    <section>                        <article>                                                        <div class="w-photos">                            	                                                                <div class="mod drug-photos">                                <h2><a>View Package Photos</a></h2>                                <ul>                                    <li>                                                                               <ul>                                                                                                                        	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=image-02.jpg&setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="0">                                                 	<img id="zoom_1" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=image-02.jpg&setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" src="image.cfm?type=img&name=image-02.jpg&setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                	                                            	 <li class="img package-photo"><a href="image.cfm?type=img&name=image-03.jpg&setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" class="thumbnail" title="Package Photo" data-photo-type="package" data-slideorder="1">                                                 	<img id="zoom_2" title="Package Photo" alt="Package Photo"                                                     data-zoom-image="image.cfm?type=img&name=image-03.jpg&setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" src="image.cfm?type=img&name=image-03.jpg&setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" data-photo-type="package">                                                 	<span class="enlarge"></span>                                                    </a></li>                                                                                             											                                                                                </ul>                                    </li>                                </ul>								                                </div>            								                                                                                            </div>                            <div class="mod-wrap">                                <div class="mod blue-list page-jump">                                    <h2><a href="#drug-information">Drug Label Info</a></h2>                                </div>                                                                <div class="mod blue-list orange">                                                                                                                                                                                                                                                                                                                                                                            <h2><a href="#">Safety</a></h2>                                    <ul>                                                                                    <li>                                                <a class="tip" rel="tooltip" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects." href="#boxedwarning">Boxed Warnings</a>                                            </li>                                                                                                                                                                    <li>                                                <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>                                            </li>                                            <li><a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a></li>                                            <li>                                                <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22DESVENLAFAXINE%22+%29" target="_blank">Presence in Breast Milk</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">Related Resources</a></h2>                                    <ul>                                                                                                                            <li>                                                <a href="/vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=DESVENLAFAXINE" target="_blank">Medline Plus</a>                                            </li>                                                                                <li>                                            <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=DESVENLAFAXINE" target="blank">Clinical Trials</a>                                        </li>                                                                                    <li>                                                <a href="#" id="pubmed-menu">PubMed</a>                                            	    											                                                                                                <ul>                                                    <li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a>                                                    </li>                                					<li>                                                        <a href="/www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=DESVENLAFAXINE[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a>                                                    </li>                                                </ul>                                            </li>                                            <li>                                                <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=DESVENLAFAXINE+SUCCINATE&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                            </li>                                                                            </ul>                                </div>                                <div class="mod blue-list">                                    <h2><a href="#">More Info For This Drug</a></h2>                                    <ul>                                    	                                        <li><a href="#modal-label-archives" class="modal-open">View Label Archives</a></li>                                        <li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>                                                                                <li><a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a></li>                                    </ul>                                </div>                                                            </div>                        </article>                    </section>                </div>                               <div class="content-wide">                        <article>                            <ul class="drug-information">                            	                                                                <li>                                <strong><a class="tip" rel="tooltip" title="NDC (National Drug Code) - Each drug product is assigned this unique number which can be found on the drug's outer packaging." href="#">NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    55154-4230-2,                                                                                                                                        	                                    55154-4230-8,                                                                                                                                        	                                    55154-4235-8                                                                                                                                                                        								</li>                                <li>                                                                                                                                                                <li><strong>Packager: </strong>Cardinal Health</li>                                						    	    																																			    																	    	    	                             		       	                                                                                                                                                               <li><strong>This is a repackaged label.</strong></li>                                <li>                                <strong><a class="tip" rel="tooltip" title="This is a repackaged label. The source NDC Code refers to the unique number assigned to the original label." href="#">Source NDC Code(s):</a></strong> <span id="item-code-s">                                                                                                	                                    <a href="dailymed/search.cfm?searchdb=ndc&query=0008-1211">0008-1211</a>,                                                                                                                                        	                                    <a href="dailymed/search.cfm?searchdb=ndc&query=0008-1222">0008-1222</a>                                                                                                                                                                        								</li>                                                            </ul>                                                        <ul class="drug-information">                            	                                <li><strong>Category:</strong>                                 	                                    	<span id="category" class="orangetext">                                                                            	HUMAN PRESCRIPTION DRUG LABEL</span></li>                                                                    <li><strong>DEA Schedule:</strong> <span id="dea-schedule">                                                                        	None                                                                        </span></li>                                                                    <li><strong>Marketing Status:</strong> <span id="marketing-status">New Drug Application</span></li>								                            </ul>							                                    <div id="drug-information" class="toggle">                                                                                    <h2><a id="druglabel"></a>Drug Label Information</h2>                                                 <p class="date">Updated                                                  	                                                    	05/15                                                                                                     </p>                                                   <p class="orangetext">If you are a consumer or patient please visit <a href="dailymed/drugInfo.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&audience=consumer">this version.</a></p>                                                                                                   <ul class="tools">                                                    <li class="download">Download DRUG LABEL INFO: <a class="pdf" href="dailymed/getFile.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&amp;type=pdf&amp;name=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" target="_blank">PDF</a>                                                    	<a class="xml" href="dailymed/getFile.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&amp;type=zip&amp;name=PRISTIQ EXTENDED-RELEASE">XML</a>                                                    </li>                                                                                                                                                            <li class="medguide">Medication Guide:                                                         <a href="dailymed/medguide.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" target="_blank">HTML</a>                                                                                                            </li>                                                                                                        <li class="print">                                                        <a href="dailymed/fda/fdaDrugXsl.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&amp;type=display" target="_blank">Print Drug Label Info</a>                                                    </li>                                                                                                    </ul>                                                                                                  <div class="drug-label-sections">                                                   <div class="control-nav show-js">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                                                        <ul>                                                                                        	                                                <li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip" rel="tooltip" href="#" title="A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What is this?)</a> <div class="Warning toggle-content open">   <a name="BOX"></a>  <a name="section-1"></a>   <p></p>   <h1> <span class="Emphasis">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</span> </h1>   <p class="First"> <span class="Bold">Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]. </span> </p>   <p> <span class="Bold">In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber [<span class="Italics">see <a href="#S5.1">Warnings and Precautions (5.1)</a></span>]. </span> </p>   <p> <span class="Bold">PRISTIQ is not approved for use in pediatric patients [<span class="Italics">see <a href="#S8.4">Use in Specific Populations (8.4)</a></span>].</span> </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a> <div id="Highlights" class=" Highlights toggle-content closed">    <div class="HighlightsDisclaimer">   These highlights do not include all the information needed to use PRISTIQ safely and effectively. See full prescribing information for PRISTIQ.    <br />    <br />PRISTIQ   <span class="Sup">&reg;</span> (desvenlafaxine) Extended-Release Tablets, for oral use    <br />Initial U.S. Approval: 2008  </div>   <div class="Warning">    <div>     <h1 class="Warning">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>     <h1 class="Warning"> <span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span> </h1>     <dl>      <dt>      •     </dt>      <dd>       <span class="Bold">Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants (<a href="#S5.1">5.1</a>).</span>      </dd>      <dt>      •     </dt>      <dd>       <span class="Bold">Monitor for worsening and emergence of suicidal thoughts and behaviors (<a href="#S5.1">5.1</a>).</span>      </dd>      <dt>      •     </dt>      <dd>       <span class="Bold">PRISTIQ is not approved for use in pediatric patients (<a href="#S8.4">8.4</a>).</span>      </dd>     </dl>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>RECENT MAJOR CHANGES</span> </h1>    <div>     <table width="100%">      <colgroup>      <col width="90%" />       <col width="10%" />      </colgroup>     <tbody class="Headless">       <tr>        <td class="Toprule"> <p class="Highlighta">Dosage and Administration, General Instruction for Use (<a href="#S2.1">2.1</a>) </p> </td>       <td class="Toprule"> <p class="Highlighta">04/2014 </p> </td>       </tr>       <tr>        <td> <p class="Highlighta">Dosage and Administration, Special populations (<a href="#S2.2">2.2</a>) </p> </td>       <td> <p class="Highlighta">07/2014 </p> </td>       </tr>       <tr>        <td> <p class="Highlighta">Dosage and Administration, Discontinuing PRISTIQ (<a href="#S2.4">2.4</a>) </p> </td>       <td> <p class="Highlighta">04/2014 </p> </td>       </tr>       <tr>        <td class="Botrule"> <p class="Highlighta">Warnings and Precautions, Angle Closure Glaucoma(<a href="#S5.5">5.5</a>) </p> </td>       <td class="Botrule"> <p class="Highlighta">05/2014 </p> </td>       </tr>      </tbody>     </table>    </div>   </div>   <div></div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>INDICATIONS AND USAGE</span> </h1>    <div>     <p class="Highlighta">PRISTIQ, is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of major depressive disorder (MDD) (<a href="#S1">1</a>). </p>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE AND ADMINISTRATION</span> </h1>    <div>     <dl>      <dt>      •     </dt>      <dd>      Recommended dose: 50 mg once daily with or without food (      <a href="#S2.1">2.1</a>).      </dd>      <dt>      •     </dt>      <dd>      There was no evidence that doses greater than 50 mg per day confer any additional benefit (      <a href="#S2.1">2.1</a>).     </dd>      <dt>      •     </dt>      <dd>      The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment or dosing in severe renal and end-stage renal disease patients (      <a href="#S2.1">2.1</a>).      </dd>      <dt>      •     </dt>      <dd>      Discontinuation: Reduce dose gradually whenever possible (      <a href="#S2.1">2.1</a>).      </dd>      <dt>      •     </dt>      <dd>      Take tablets whole; do not divide, crush, chew, or dissolve (      <a href="#S2.1">2.1</a>).      </dd>      <dt>      •     </dt>      <dd>      Moderate renal impairment: Maximum dose 50 mg per day (      <a href="#S2.2">2.2</a>).      </dd>      <dt>      •     </dt>      <dd>      Severe renal impairment and end-stage renal disease: Maximum dose 25 mg per day or 50 mg every other day (      <a href="#S2.2">2.2</a>).     </dd>      <dt>      •     </dt>      <dd>      Moderate to severe hepatic impairment: Maximum dose 100 mg per day (      <a href="#S2.2">2.2</a>).      </dd>     </dl>    </div>    <div></div>    <div>     <div></div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div>     <div></div>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>DOSAGE FORMS AND STRENGTHS</span> </h1>    <div>     <dl>      <dt>      •     </dt>      <dd>      PRISTIQ extended-release tablets: 25 mg, 50 mg and 100 mg (      <a href="#S3">3</a>).      </dd>      <dt>      •     </dt>      <dd>      Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively (      <a href="#S3">3</a>).      </dd>     </dl>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>CONTRAINDICATIONS</span> </h1>    <div>     <dl>      <dt>      •     </dt>      <dd>      Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or any excipients in the PRISTIQ formulation (4.1).      </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Serotonin syndrome and MAOIs</span>: Do not use MAOIs intended to treat psychiatric disorders with PRISTIQ or within 7 days of stopping treatment with PRISTIQ. Do not use PRISTIQ within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start PRISTIQ in a patient who is being treated with linezolid or intravenous methylene blue (4.2).      </dd>     </dl>    </div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>WARNINGS AND PRECAUTIONS</span> </h1>    <div>     <dl>      <dt>      •     </dt>      <dd>       <span class="Italics">Clinical Worsening/Suicide Risk:</span> Monitor for clinical worsening and suicide risk (      <a href="#S5.1">5.1</a>).      </dd>      <dt>      •     </dt>      <dd>       <span class="ItalicsItalics">Serotonin Syndrome:</span> Serotonin syndrome has been reported with SSRIs and SNRIs, including with PRISTIQ, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort). If such symptoms occur, discontinue PRISTIQ and initiate supportive treatment. If concomitant use of PRISTIQ with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases (      <a href="#S5.2">5.2</a>).     </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Elevated Blood Pressure:</span> Control hypertension before initiating treatment. Monitor blood pressure regularly during treatment (      <a href="#S5.3">5.3</a>).      </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Abnormal Bleeding:</span> PRISTIQ may increase risk of bleeding events. Caution patients about risk of bleeding associated with concomitant use of PRISTIQ and NSAIDs, aspirin, or other drugs that affect coagulation (      <a href="#S5.4">5.4</a>).      </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Angle Closure Glaucoma:</span> Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants. (      <a href="#S5.5">5.5</a>)     </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Activation of Mania/Hypomania:</span> Use cautiously in patients with Bipolar Disorder. Caution patients about risk of activation of mania/hypomania (      <a href="#S5.6">5.6</a>).      </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Discontinuation Syndrome:</span> Taper dose when possible and monitor for discontinuation symptoms (      <a href="#S5.7">5.7</a>).      </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Seizure:</span> Can occur. Use cautiously in patients with seizure disorder (      <a href="#S5.8">5.8</a>).      </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Hyponatremia:</span> Can occur in association with SIADH (      <a href="#S5.9">5.9</a>).      </dd>      <dt>      •     </dt>      <dd>       <span class="Italics">Interstitial Lung Disease and Eosinophilic Pneumonia:</span> Can occur (      <a href="#S5.10">5.10</a>).      </dd>     </dl>    </div>    <div>     <div></div>    </div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>ADVERSE REACTIONS</span> </h1>    <div>     <p class="Highlighta">Most common adverse reactions (incidence ≥5% and twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders (<a href="#S6.1">6.1</a>). </p>     <p class="Highlighta"> <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc., at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>    </div>    <div>     <div></div>     <div></div>     <div></div>     <div></div>     <div>      <div>       <div></div>       <div></div>       <div></div>       <div></div>      </div>     </div>    </div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div class="HighlightSection">    <h1 class="Highlights"> <span>USE IN SPECIFIC POPULATIONS</span> </h1>    <div>     <dl>      <dt>      •     </dt>      <dd>      Pregnancy: Based on animal data, may cause fetal harm (      <a href="#S8.1">8.1</a>).      </dd>      <dt>      •     </dt>      <dd>      Nursing Mothers: Discontinue drug or nursing taking into consideration importance of drug to mother (      <a href="#S8.3">8.3</a>).     </dd>      <dt>      •     </dt>      <dd>      Geriatric Use: There is an increased incidence of orthostatic hypotension in desvenlafaxine treated patients ≥ 65 years (      <a href="#S6.1">6.1</a> and       <a href="#S8.5">8.5</a>).     </dd>     </dl>    </div>    <div>     <div>      <div></div>      <div></div>      <div></div>      <div></div>     </div>    </div>    <div></div>    <div></div>    <div>     <div></div>     <div></div>    </div>   </div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>   </div>   <div></div>   <div>    <div></div>    <div>     <div></div>    </div>    <div>     <div></div>     <div></div>     <div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>     </div>     <div>      <div></div>      <div></div>      <div></div>      <div></div>      <div></div>     </div>    </div>   </div>   <div>    <div>     <div></div>     <div></div>     <div></div>    </div>   </div>   <div></div>   <div>    <div></div>   </div>   <div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>    <div></div>   </div>   <div></div>   <div></div>   <div></div>   <p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>   <p class="HighlightsRevision">Revised: 3/2015</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a> <div id="Index" class=" Index toggle-content closed">    <h1> <a href="#section-1" class="toc"><span class="Emphasis">WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</span></a> </h1>   <h1> <a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a> </h1>   <h1> <a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a> </h1>   <h2> <a href="#section-2.1" class="toc">2.1 GENERAL INSTRUCTION FOR USE</a> </h2>   <h2> <a href="#section-2.2" class="toc">2.2 Special Populations </a> </h2>   <h2> <a href="#section-2.3" class="toc">2.3 Maintenance/Continuation/Extended Treatment </a> </h2>   <h2> <a href="#section-2.4" class="toc">2.4 Discontinuing PRISTIQ </a> </h2>   <h2> <a href="#section-2.5" class="toc">2.5 Switching Patients From Other Antidepressants to PRISTIQ</a> </h2>   <h2> <a href="#section-2.6" class="toc">2.6 Switching Patients To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders </a> </h2>   <h1> <a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a> </h1>   <h1> <a href="#section-4" class="toc">4 CONTRAINDICATIONS</a> </h1>   <h1> <a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a> </h1>   <h2> <a href="#section-5.1" class="toc">5.1 Suicidal Thoughts and Behaviors in Children, Adolescents and Young Adults </a> </h2>   <h2> <a href="#section-5.2" class="toc">5.2 Serotonin Syndrome </a> </h2>   <h2> <a href="#section-5.3" class="toc">5.3 Elevated Blood Pressure </a> </h2>   <h2> <a href="#section-5.4" class="toc">5.4 Abnormal Bleeding </a> </h2>   <h2> <a href="#section-5.5" class="toc">5.5 Angle Closure Glaucoma </a> </h2>   <h2> <a href="#section-5.6" class="toc">5.6 Activation of Mania/Hypomania </a> </h2>   <h2> <a href="#section-5.7" class="toc">5.7 Discontinuation Syndrome </a> </h2>   <h2> <a href="#section-5.8" class="toc">5.8 Seizure </a> </h2>   <h2> <a href="#section-5.9" class="toc">5.9 Hyponatremia </a> </h2>   <h2> <a href="#section-5.10" class="toc">5.10 Interstitial Lung Disease and Eosinophilic Pneumonia </a> </h2>   <h1> <a href="#section-6" class="toc">6 ADVERSE REACTIONS</a> </h1>   <h2> <a href="#section-6.1" class="toc">6.1 Clinical Studies Experience </a> </h2>   <h2> <a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a> </h2>   <h1> <a href="#section-7" class="toc">7 DRUG INTERACTIONS</a> </h1>   <h2> <a href="#section-7.1" class="toc">7.1 Monoamine Oxidase Inhibitors (MAOI) </a> </h2>   <h2> <a href="#section-7.2" class="toc">7.2 Serotonergic Drugs</a> </h2>   <h2> <a href="#section-7.3" class="toc">7.3 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) </a> </h2>   <h2> <a href="#section-7.4" class="toc">7.4 Potential for Other Drugs to Affect Desvenlafaxine </a> </h2>   <h2> <a href="#section-7.5" class="toc">7.5 Potential for Desvenlafaxine to Affect Other Drugs </a> </h2>   <h2> <a href="#section-7.6" class="toc">7.6 Other Drugs Containing Desvenlafaxine or Venlafaxine</a> </h2>   <h2> <a href="#section-7.7" class="toc">7.7 Ethanol </a> </h2>   <h2> <a href="#section-7.8" class="toc">7.8 Drug-Laboratory Test Interactions</a> </h2>   <h1> <a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a> </h1>   <h2> <a href="#section-8.1" class="toc">8.1 Pregnancy</a> </h2>   <h2> <a href="#section-8.2" class="toc">8.3 Nursing Mothers</a> </h2>   <h2> <a href="#section-8.3" class="toc">8.4 Pediatric Use</a> </h2>   <h2> <a href="#section-8.4" class="toc">8.5 Geriatric Use</a> </h2>   <h2> <a href="#section-8.5" class="toc">8.6 Other Patient Factors </a> </h2>   <h1> <a href="#section-9" class="toc">9 DRUG ABUSE AND DEPENDENCE</a> </h1>   <h2> <a href="#section-9.1" class="toc">9.1 Controlled Substance</a> </h2>   <h1> <a href="#section-10" class="toc">10 OVERDOSAGE</a> </h1>   <h2> <a href="#section-10.1" class="toc">10.1 Human Experience with Overdosage </a> </h2>   <h2> <a href="#section-10.2" class="toc">10.2 Management of Overdosage </a> </h2>   <h1> <a href="#section-11" class="toc">11 DESCRIPTION</a> </h1>   <h1> <a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a> </h1>   <h2> <a href="#section-12.1" class="toc">12.1 Mechanism of Action</a> </h2>   <h2> <a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a> </h2>   <h2> <a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a> </h2>   <h1> <a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a> </h1>   <h2> <a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a> </h2>   <h1> <a href="#section-14" class="toc">14 CLINICAL STUDIES</a> </h1>   <h1> <a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a> </h1>   <h1> <a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a> </h1>   <dl class="Footnote">    <dt>     <a name="footnote-content" href="#footnote-reference-content">*</a>    </dt>    <dd>    Sections or subsections omitted from the full prescribing information are not listed.   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">1 INDICATIONS AND USAGE</a> <div class="Section toggle-content closed" data-sectioncode="34067-9">   <a name="S1"></a>  <a name="section-1"></a>   <p></p>    <p class="First">PRISTIQ, a serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD) <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a> and <a href="#S2.1">Dosage and Administration (2.1)</a>]</span>. The efficacy of PRISTIQ has been established in four short-term (8-week, placebo-controlled studies) and two maintenance studies in adult outpatients who met DSM-IV criteria for major depressive disorder. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">2 DOSAGE AND ADMINISTRATION</a> <div class="Section toggle-content closed" data-sectioncode="34068-7">   <a name="S2"></a>  <a name="section-2"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S2.1"></a>   <a name="section-2.1"></a>    <p></p>    <h2>2.1 GENERAL INSTRUCTION FOR USE</h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">The recommended dose for PRISTIQ is 50 mg once daily, with or without food. The 50 mg dose is both a starting dose and the therapeutic dose. PRISTIQ should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.</span> </p>    <p style="border-left:1px solid;"> <span class="XmChange">In clinical studies, doses of 10 mg to 400 mg per day were studied. In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day and adverse reactions and discontinuations were more frequent at higher doses.</span> </p>    <p style="border-left:1px solid;"> <span class="XmChange">The 25 mg per day dose is intended for a gradual reduction in dose when discontinuing treatment. When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#S2.4">Dosage and Administration (2.4)</a><span class="XmChange"> and </span><a href="#S5.9">Warnings and Precautions (5.9)</a><span class="XmChange">]</span></span><span class="XmChange">.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.2"></a>   <a name="section-2.2"></a>    <p></p>    <h2>2.2 Special Populations </h2>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_ebeb3c2b-4453-49e1-83d7-a76814f50ed3"></a>    <a name="section-2.2.1"></a>     <p></p>     <p class="First" style="border-left:1px solid;"> <span class="XmChange"><span class="Underline">Patients with renal impairment</span></span> </p>     <p style="border-left:1px solid;"> <span class="XmChange">The maximum recommended dose in patients with moderate renal impairment (24-hr creatinine clearance [CrCl] = 30 to 50 mL/min, Cockcroft-Gault [C-G]) is 50 mg per day. The maximum recommended dose in patients with severe renal impairment (24-hr CrCl less than 30 mL/min, C-G) or end-stage renal disease (ESRD) is 25 mg every day or 50 mg every other day. Supplemental doses should not be given to patients after dialysis <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#S8.6">Use in Specific Populations (8.6)</a><span class="XmChange"> and </span><a href="#S12.3">Clinical Pharmacology (12.3)</a><span class="XmChange">]</span></span><span class="XmChange">. </span> </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_36b3581a-d6bb-44c1-b0c5-71c8ab5943e1"></a>    <a name="section-2.2.2"></a>     <p></p>     <p class="First"> <span class="Underline">Patients with hepatic impairment</span> </p>     <p>The recommended dose in patients with moderate to severe hepatic impairment is 50 mg per day. Dose escalation above 100 mg per day is not recommended <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.3"></a>   <a name="section-2.3"></a>    <p></p>    <h2>2.3 Maintenance/Continuation/Extended Treatment </h2>    <p class="First">It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Longer-term efficacy of PRISTIQ (50–400 mg) was established in two maintenance trials <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. Patients should be periodically reassessed to determine the need for continued treatment.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.4"></a>   <a name="section-2.4"></a>    <p></p>    <h2>2.4 Discontinuing PRISTIQ </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Symptoms associated with discontinuation of PRISTIQ, other SNRIs and SSRIs have been reported <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#S5.9">Warnings and Precautions (5.9)</a><span class="XmChange">]</span></span><span class="XmChange">. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate. The 25 mg dose is available for discontinuing therapy.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.5"></a>   <a name="section-2.5"></a>    <p></p>    <h2>2.5 Switching Patients From Other Antidepressants to PRISTIQ</h2>    <p class="First">Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to PRISTIQ. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S2.6"></a>   <a name="section-2.6"></a>    <p></p>    <h2>2.6 Switching Patients To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders </h2>    <p class="First">At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with PRISTIQ. Conversely, at least 7 days should be allowed after stopping PRISTIQ before starting an MAOI intended to treat psychiatric disorders [<span class="Italics">see Contraindications (4.2)</span>]. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_968a081d-3c48-41a9-bd3e-19224e81b8da"></a>    <a name="section-2.6.1"></a>     <p></p>     <p class="First"> <span class="Bold">Use of PRISTIQ with other MAOIs such as Linezolid or Methylene Blue </span> </p>     <p>Do not start PRISTIQ in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered <span class="Italics">[see Contraindications (4.2)]</span>.</p>     <p>In some cases, a patient already receiving PRISTIQ therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, PRISTIQ should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 7 days or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with PRISTIQ may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>     <p>The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with PRISTIQ is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a> <div class="Section toggle-content closed" data-sectioncode="43678-2">   <a name="S3"></a>  <a name="section-3"></a>   <p></p>    <p class="First">PRISTIQ<span class="Sup">&reg;</span> (desvenlafaxine) Extended-Release Tablets are available as 25 mg, 50 mg and 100 mg tablets.</p>   <p>25 mg, tan, square pyramid tablet debossed with &quot;W&quot; over &quot;25&quot; on the flat side</p>   <p>50 mg, light pink, square pyramid tablet debossed with &quot;W&quot; over &quot;50&quot; on the flat side </p>   <p>100 mg, reddish-orange, square pyramid tablet debossed with &quot;W&quot; over &quot;100&quot; on the flat side </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">4 CONTRAINDICATIONS</a> <div class="Section toggle-content closed" data-sectioncode="34070-3">   <a name="S4"></a>  <a name="section-4"></a>   <p></p>    <dl>    <dt>    •   </dt>    <dd>    Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the PRISTIQ formulation. Angioedema has been reported in patients treated with PRISTIQ     <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.   </dd>    <dt>    •   </dt>    <dd>    The use of MAOIs intended to treat psychiatric disorders with PRISTIQ or within 7 days of stopping treatment with PRISTIQ is contraindicated because of an increased risk of serotonin syndrome. The use of PRISTIQ within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated     <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a></span> and     <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a>].</span>    </dd>    <dt>    •   </dt>    <dd>    Starting PRISTIQ in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see     <a href="#S2.6">Dosage and Administration (2.6)</a> and     <a href="#S5.2">Warnings and Precautions (5.2)</a>].   </dd>   </dl>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">5 WARNINGS AND PRECAUTIONS</a> <div class="Section toggle-content closed" data-sectioncode="43685-7">   <a name="S5"></a>  <a name="section-5"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S5.1"></a>   <a name="section-5.1"></a>    <p></p>    <h2>5.1 Suicidal Thoughts and Behaviors in Children, Adolescents and Young Adults </h2>    <p class="First">Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. </p>    <p>The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1. </p>    <a name="_Reftable1"></a>    <div class="scrollingtable">    <table width="75%">      <caption>       <span>Table 1</span>      </caption>      <colgroup>      <col width="18%" />       <col width="69%" />      </colgroup>     <thead>       <tr class="First Last">        <th class="Botrule Lrule Rrule Toprule" align="left" valign="bottom"><span class="Bold">Age Range </span></th>       <th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Drug-Placebo Difference in Number of Cases of Suicidality per 1,000 Patients Treated</span></th>       </tr>      </thead>      <tbody>       <tr class="First">        <td class="Botrule Lrule Rrule Toprule"></td>       <td class="Botrule Rrule Toprule"> <p class="First">Increases Compared to Placebo </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">&lt;18</p> </td>       <td class="Botrule Rrule"> <p class="First"> 14 additional cases </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">18 to 24</p> </td>       <td class="Botrule Rrule"> <p class="First">5 additional cases </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"></td>       <td class="Botrule Rrule"> <p class="First">Decreases Compared to Placebo </p> </td>       </tr>       <tr>        <td class="Botrule Lrule Rrule"> <p class="First">25 to 64</p> </td>       <td class="Botrule Rrule"> <p class="First">1 fewer case </p> </td>       </tr>       <tr class="Last">        <td class="Botrule Lrule Rrule"> <p class="First">≥65 </p> </td>       <td class="Botrule Rrule"> <p class="First">6 fewer cases</p> </td>       </tr>      </tbody>     </table>   </div>    <p>No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide. </p>    <p>It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression. </p>    <p> <span class="Bold">All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.</span> </p>    <p>The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. </p>    <p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. </p>    <p>If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S5.7">Warnings and Precautions (5.7)</a> for a description of the risks of discontinuation of PRISTIQ]</span>. </p>    <p> <span class="Bold">Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers</span>.</p>    <p>Prescriptions for PRISTIQ should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_0858715c-cf80-4f26-bcf6-cab5f4561255"></a>    <a name="section-5.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Screening patients for bipolar disorder</span> </p>     <p>A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that PRISTIQ is not approved for use in treating bipolar depression. </p>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.2"></a>   <a name="section-5.2"></a>    <p></p>    <h2>5.2 Serotonin Syndrome </h2>    <p class="First">The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including PRISTIQ, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). </p>    <p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome. </p>    <p>The concomitant use of PRISTIQ with MAOIs intended to treat psychiatric disorders is contraindicated. PRISTIQ should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking PRISTIQ. PRISTIQ should be discontinued before initiating treatment with the MAOI <span class="Italics">[see Contraindications (4.2)</span> and <span class="Italics"><a href="#S2.6">Dosage and Administration (2.6)</a>]</span>.</p>    <p>If concomitant use of PRISTIQ with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. </p>    <p>Treatment with PRISTIQ and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.3"></a>   <a name="section-5.3"></a>    <p></p>    <h2>5.3 Elevated Blood Pressure </h2>    <p class="First">Patients receiving PRISTIQ should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. Pre-existing hypertension should be controlled before initiating treatment with PRISTIQ. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with PRISTIQ. </p>    <p>Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving PRISTIQ, either dose reduction or discontinuation should be considered <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.4"></a>   <a name="section-5.4"></a>    <p></p>    <h2>5.4 Abnormal Bleeding </h2>    <p class="First">SSRIs and SNRIs, including PRISTIQ, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of PRISTIQ and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.5"></a>   <a name="section-5.5"></a>    <p></p>    <h2>5.5 Angle Closure Glaucoma </h2>    <p class="First" style="border-left:1px solid;"> <span class="XmChange">Angle-Closure Glaucoma: The pupillary dilation that occurs following use of many antidepressant drugs including Pristiq may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy.</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.6"></a>   <a name="section-5.6"></a>    <p></p>    <h2>5.6 Activation of Mania/Hypomania </h2>    <p class="First">During all MDD phase 2 and phase 3 studies, mania was reported for approximately 0.02% of patients treated with PRISTIQ. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, PRISTIQ should be used cautiously in patients with a history or family history of mania or hypomania. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.7"></a>   <a name="section-5.7"></a>    <p></p>    <h2>5.7 Discontinuation Syndrome </h2>    <p class="First">Discontinuation symptoms have been systematically and prospectively evaluated in patients treated with PRISTIQ during clinical studies in Major Depressive Disorder. Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy. </p>    <p>During marketing of SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. </p>    <p>Patients should be monitored for these symptoms when discontinuing treatment with PRISTIQ. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.8"></a>   <a name="section-5.8"></a>    <p></p>    <h2>5.8 Seizure </h2>    <p class="First">Cases of seizure have been reported in pre-marketing clinical studies with PRISTIQ. PRISTIQ has not been systematically evaluated in patients with a seizure disorder. Patients with a history of seizures were excluded from pre-marketing clinical studies. PRISTIQ should be prescribed with caution in patients with a seizure disorder. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.9"></a>   <a name="section-5.9"></a>    <p></p>    <h2>5.9 Hyponatremia </h2>    <p class="First">Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a> and Clinical Pharmacology (12.6)]</span>. Discontinuation of PRISTIQ should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted. </p>    <p>Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S5.10"></a>   <a name="section-5.10"></a>    <p></p>    <h2>5.10 Interstitial Lung Disease and Eosinophilic Pneumonia </h2>    <p class="First">Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of PRISTIQ) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with PRISTIQ who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of PRISTIQ should be considered. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">6 ADVERSE REACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34084-4">   <a name="S6"></a>  <a name="section-6"></a>   <p></p>    <p class="First">The following adverse reactions are discussed in greater detail in other sections of the label. </p>   <dl>    <dt>    •   </dt>    <dd>    Hypersensitivity     <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Suicidal Thoughts and Behaviors in Adolescents and Young Adults     <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Serotonin Syndrome     <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Elevated Blood Pressure     <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Abnormal Bleeding     <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Angle Closure Glaucoma [    <span class="Italics">see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Activation of Mania/Hypomania     <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Discontinuation Syndrome     <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Seizure     <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Hyponatremia     <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>    </dd>    <dt>    •   </dt>    <dd>    Interstitial Lung Disease and Eosinophilic Pneumonia     <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>    </dd>   </dl>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.1"></a>   <a name="section-6.1"></a>    <p></p>    <h2>6.1 Clinical Studies Experience </h2>    <p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_9befa759-055a-4e4a-b261-4119a958b9f4"></a>    <a name="section-6.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Patient exposure</span> </p>     <p>PRISTIQ was evaluated for safety in 8,394 patients diagnosed with major depressive disorder who participated in multiple-dose pre-marketing studies, representing 2,784 patient-years of exposure. Of the total 8,394 patients exposed to at least one dose of PRISTIQ; 2,116 were exposed to PRISTIQ for 6 months, representing 1,658 patient-years of exposure, and 421 were exposed for one year, representing 416 patient-years of exposure. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_047269a8-7cd8-4627-bcab-7bdb49a455b6"></a>    <a name="section-6.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Adverse reactions reported as reasons for discontinuation of treatment</span> </p>     <p>In the pre-marketing pooled 8-week placebo-controlled studies in patients with MDD, 1,834 patients were exposed to PRISTIQ (50 to 400 mg). Of the 1,834 patients, 12% discontinued treatment due to an adverse reaction, compared with 3% of the 1,116 placebo-treated patients. At the recommended dose of 50 mg, the discontinuation rate due to an adverse reaction for PRISTIQ (4.1%) was similar to the rate for placebo (3.8%). For the 100 mg dose of PRISTIQ the discontinuation rate due to an adverse reaction was 8.7%. </p>     <p>The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the PRISTIQ treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each). In a longer-term study, up to 9 months, the most common was vomiting (2%). </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_88ccc8a1-6183-4069-8110-3196a907edde"></a>    <a name="section-6.1.3"></a>     <p></p>     <p class="First"> <span class="Underline">Common adverse reactions in placebo-controlled MDD studies</span> </p>     <p>The most commonly observed adverse reactions in PRISTIQ treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence ≥ 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders. </p>     <p>Table 2 shows the incidence of common adverse reactions that occurred in ≥ 2% of PRISTIQ treated MDD patients and twice the rate of placebo at any dose in the pre-marketing pooled 8-week, placebo-controlled, fixed dose clinical studies </p>     <a name="_Reftable2"></a>     <div class="scrollingtable">     <table width="90%">       <caption>        <span>Table 2: Common Adverse Reactions (≥ 2% in any Fixed-Dose Group and Twice the Rate of Placebo) in Pre-marketing Pooled MDD 8-Week Placebo-Controlled Studies</span>       </caption>       <colgroup>       <col width="25%" />        <col width="15%" />        <col width="15%" />        <col width="15%" />        <col width="15%" />        <col width="15%" />       </colgroup>      <thead>        <tr class="First">         <th class="Botrule Toprule" align="left" valign="top"></th>        <th class="Botrule Toprule" align="left" colspan="5" valign="top"><span class="Bold">Percentage of Patients Reporting Reaction </span></th>        </tr>        <tr>         <th align="left" valign="top"></th>        <th align="left" valign="top"></th>        <th class="Botrule" align="left" colspan="4" valign="top"><span class="Bold">PRISTIQ</span></th>        </tr>        <tr class="Last">         <th class="Botrule" align="left" valign="top"><span class="Bold">System Organ Class</span> <br /> <span class="Bold">Preferred Term</span></th>        <th class="Botrule" align="left" valign="top"><span class="Bold">Placebo</span> <br /> <span class="Bold">(n=636)</span></th>        <th class="Botrule" align="left" valign="top"><span class="Bold">50 mg</span> <br /> <span class="Bold">(n=317)</span></th>        <th class="Botrule" align="left" valign="top"><span class="Bold">100 mg</span> <br /> <span class="Bold">(n=424)</span></th>        <th class="Botrule" align="left" valign="top"><span class="Bold">200 mg</span> <br /> <span class="Bold">(n=307)</span></th>        <th class="Botrule" align="left" valign="top"><span class="Bold">400 mg</span> <br /> <span class="Bold">(n=317)</span></th>        </tr>       </thead>       <tbody>        <tr class="First">         <td class="Toprule" colspan="6"> <p class="First"> <span class="Bold">Cardiac disorders</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Blood pressure increased</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">2 </p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Gastrointestinal disorders</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Nausea </p> </td>        <td> <p class="First">10</p> </td>        <td> <p class="First">22 </p> </td>        <td> <p class="First">26</p> </td>        <td> <p class="First">36</p> </td>        <td> <p class="First">41</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Dry mouth</p> </td>        <td> <p class="First">9</p> </td>        <td> <p class="First">11</p> </td>        <td> <p class="First">17</p> </td>        <td> <p class="First">21</p> </td>        <td> <p class="First">25 </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Constipation</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">9</p> </td>        <td> <p class="First">9</p> </td>        <td> <p class="First">10</p> </td>        <td> <p class="First">14 </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Vomiting</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">6</p> </td>        <td> <p class="First">9</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">General disorders and administration site conditions</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Fatigue</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">7</p> </td>        <td> <p class="First">7</p> </td>        <td> <p class="First">10</p> </td>        <td> <p class="First">11</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Chills</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">&lt;1</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">4 </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Feeling jittery</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">3</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Metabolism and nutrition disorders</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Decreased appetite</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">5</p> </td>        <td> <p class="First">8</p> </td>        <td> <p class="First">10</p> </td>        <td> <p class="First">10</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Nervous system disorders</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Dizziness</p> </td>        <td> <p class="First">5</p> </td>        <td> <p class="First">13</p> </td>        <td> <p class="First">10</p> </td>        <td> <p class="First">15</p> </td>        <td> <p class="First">16</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Somnolence</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">9</p> </td>        <td> <p class="First">12</p> </td>        <td> <p class="First">12</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Tremor</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">9</p> </td>        <td> <p class="First">9</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Disturbance in attention</p> </td>        <td> <p class="First">&lt;1</p> </td>        <td> <p class="First">&lt;1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">1</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Psychiatric disorders</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Insomnia</p> </td>        <td> <p class="First">6</p> </td>        <td> <p class="First">9</p> </td>        <td> <p class="First">12</p> </td>        <td> <p class="First">14</p> </td>        <td> <p class="First">15</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Anxiety</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">5</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">4</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Nervousness</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">&lt;1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">2</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Abnormal dreams</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">4</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Renal and urinary disorders</span> </p> </td>        </tr>        <tr>         <td class="Botrule"> <p class="First">&nbsp;&nbsp;Urinary hesitation</p> </td>        <td class="Botrule"> <p class="First">0</p> </td>        <td class="Botrule"> <p class="First">&lt;1</p> </td>        <td class="Botrule"> <p class="First">1</p> </td>        <td class="Botrule"> <p class="First">2</p> </td>        <td class="Botrule"> <p class="First">2</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Respiratory, thoracic and mediastinal disorders</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Yawning</p> </td>        <td> <p class="First">&lt;1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">3</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Skin and subcutaneous tissue disorders</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Hyperhidrosis</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">10</p> </td>        <td> <p class="First">11</p> </td>        <td> <p class="First">18</p> </td>        <td> <p class="First">21</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Special Senses</span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Vision blurred</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">4</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Mydriasis</p> </td>        <td> <p class="First">&lt;1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">6</p> </td>        <td> <p class="First">6</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Vertigo</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">5</p> </td>        <td> <p class="First">3</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Tinnitus</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Dysgeusia</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold">Vascular disorders</span> </p> </td>        </tr>        <tr class="Last">         <td class="Botrule"> <p class="First">&nbsp;&nbsp;Hot flush</p> </td>        <td class="Botrule"> <p class="First">&lt;1 </p> </td>        <td class="Botrule"> <p class="First">1</p> </td>        <td class="Botrule"> <p class="First">1</p> </td>        <td class="Botrule"> <p class="First">2</p> </td>        <td class="Botrule"> <p class="First">2 </p> </td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_9eafcd5a-b9b8-43af-b51f-02a73070362c"></a>    <a name="section-6.1.4"></a>     <p></p>     <p class="First"> <span class="Underline">Sexual function adverse reactions</span> </p>     <p>Table 3 shows the incidence of sexual function adverse reactions that occurred in ≥ 2% of PRISTIQ treated MDD patients in any fixed-dose group (pre-marketing pooled 8-week, placebo-controlled, fixed -dose, clinical studies).</p>     <a name="_Reftable3"></a>     <div class="scrollingtable">     <table width="90%">       <caption>        <span>Table 3: Sexual Function Adverse Reactions (≥ 2% in Men or Women in any PRISTIQ Group) During the On-Therapy Period </span>       </caption>       <colgroup>       <col width="20%" />        <col width="16%" />        <col width="16%" />        <col width="16%" />        <col width="16%" />        <col width="16%" />       </colgroup>      <tbody class="Headless">        <tr class="First">         <td class="Toprule"></td>        <td class="Toprule"></td>        <td class="Botrule Toprule" colspan="4"> <p class="First"> <span class="Bold">PRISTIQ</span> </p> </td>        </tr>        <tr>         <td class="Botrule"></td>        <td class="Botrule"> <p class="First"> <span class="Bold">Placebo</span> <br />(n=239)</p> </td>        <td class="Botrule"> <p class="First"> <span class="Bold">50 mg</span> <br />(n=108)</p> </td>        <td class="Botrule"> <p class="First"> <span class="Bold">100 mg</span> <br />(n=157)</p> </td>        <td class="Botrule"> <p class="First"> <span class="Bold">200 mg</span> <br />(n=131)</p> </td>        <td class="Botrule"> <p class="First"> <span class="Bold">400 mg</span> <br />(n=154)</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold"><span class="Italics">Men only</span></span> </p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Anorgasmia</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">5</p> </td>        <td> <p class="First">8</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Libido decreased</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">4</p> </td>        <td> <p class="First">5</p> </td>        <td> <p class="First">6</p> </td>        <td> <p class="First">3</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Orgasm abnormal</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">3</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Ejaculation delayed</p> </td>        <td> <p class="First">&lt;1</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">5</p> </td>        <td> <p class="First">7</p> </td>        <td> <p class="First">6</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Erectile dysfunction</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">3</p> </td>        <td> <p class="First">6</p> </td>        <td> <p class="First">8</p> </td>        <td> <p class="First">11</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Ejaculation disorder</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">5</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Ejaculation failure</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">2</p> </td>        <td> <p class="First">2</p> </td>        </tr>        <tr>         <td> <p class="First">&nbsp;&nbsp;Sexual dysfunction</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">1</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">0</p> </td>        <td> <p class="First">2</p> </td>        </tr>        <tr>         <td></td>        <td></td>        <td class="Botrule" colspan="4"> <p class="First"> <span class="Bold">PRISTIQ</span> </p> </td>        </tr>        <tr>         <td></td>        <td> <p class="First"> <span class="Bold">Placebo</span> <br />(n=397)</p> </td>        <td> <p class="First"> <span class="Bold">50 mg</span> <br />(n=209)</p> </td>        <td> <p class="First"> <span class="Bold">100 mg</span> <br />(n=267)</p> </td>        <td> <p class="First"> <span class="Bold">200 mg</span> <br />(n=176)</p> </td>        <td> <p class="First"> <span class="Bold">400 mg</span> <br />(n=163)</p> </td>        </tr>        <tr>         <td colspan="6"> <p class="First"> <span class="Bold"><span class="Italics">&nbsp;&nbsp;Women only</span></span> </p> </td>        </tr>        <tr class="Last">         <td class="Botrule"> <p class="First">&nbsp;&nbsp;Anorgasmia</p> </td>        <td class="Botrule"> <p class="First">0</p> </td>        <td class="Botrule"> <p class="First">1</p> </td>        <td class="Botrule"> <p class="First">1</p> </td>        <td class="Botrule"> <p class="First">0</p> </td>        <td class="Botrule"> <p class="First">3</p> </td>        </tr>       </tbody>      </table>    </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_dfb3cdce-fcaa-465b-8340-9144baf99809"></a>    <a name="section-6.1.5"></a>     <p></p>     <p class="First"> <span class="Underline">Other adverse reactions observed in premarketing and postmarketing clinical studies</span> </p>     <p>Other infrequent adverse reactions, not described elsewhere in the label, occurring at an incidence of &lt; 2% in MDD patients treated with PRISTIQ were: </p>     <p> <span class="Bold"><span class="Italics">Cardiac disorders</span></span> – Tachycardia.</p>     <p> <span class="Bold"><span class="Italics">General disorders and administration site conditions</span></span> – Asthenia.</p>     <p> <span class="Bold"><span class="Italics">Investigations –</span></span> Weight increased, liver function test abnormal, blood prolactin increased. </p>     <p> <span class="Bold"><span class="Italics">Musculoskeletal and connective tissue disorders –</span></span> Musculoskeletal stiffness.</p>     <p> <span class="Bold"><span class="Italics">Nervous system disorders –</span></span>Syncope, convulsion, dystonia. </p>     <p> <span class="Bold"><span class="Italics">Psychiatric disorders –</span></span> Depersonalization, bruxism.</p>     <p> <span class="Bold"><span class="Italics">Renal and urinary disorders</span></span> – Urinary retention.</p>     <p> <span class="Bold"><span class="Italics">Skin and subcutaneous tissue disorders </span> –</span> Rash, alopecia, photosensitivity reaction, angioedema. </p>     <p>In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during PRISTIQ treatment as compared to placebo. </p>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_b037b400-1c81-4da1-bbb7-d31ae9e5bff9"></a>     <a name="section-6.1.5.1"></a>      <p></p>      <p class="First"> <span class="Bold"><span class="Underline">Laboratory, ECG and vital sign changes observed in MDD clinical studies</span></span> </p>      <p>The following changes were observed in pre-marketing placebo-controlled, short-term MDD studies with PRISTIQ. </p>      <div class="Section" data-sectioncode="42229-5">       <a name="ID_754b145f-87d6-417d-82c8-7283bcbdc6eb"></a>      <a name="section-6.1.5.1.1"></a>       <p></p>       <p class="First"> <span class="Bold"><span class="Italics">Lipids</span></span> </p>       <p>Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potentially clinically significant. </p>       <p>The percentage of patients who exceeded a predetermined threshold value is shown in Table 4. </p>       <a name="_Reftable4"></a>       <div class="scrollingtable">       <table width="80%">         <caption>          <span>Table 4: Incidence (%) of Patients With Lipid Abnormalities of Potential Clinical Significance*</span>         </caption>         <colgroup>         <col width="32%" />          <col width="13%" />          <col width="12%" />          <col width="12%" />          <col width="12%" />          <col width="12%" />         </colgroup>        <thead>          <tr class="First">           <th class="Toprule" align="left" valign="top"></th>          <th class="Toprule" align="left" valign="top"></th>          <th class="Botrule Toprule" align="left" colspan="4" valign="top"><span class="Bold">PRISTIQ</span></th>          </tr>          <tr class="Last">           <th class="Botrule" align="left" valign="top"></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">Placebo</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">50 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">100 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">200 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">400 mg</span></th>          </tr>         </thead>         <tbody>          <tr class="First">           <td class="Toprule"> <p class="First">Total Cholesterol<br />*(Increase of ≥ 50 mg/dl and an absolute value of ≥ 261 mg/dl)</p> </td>          <td class="Toprule"> <p class="First">2</p> </td>          <td class="Toprule"> <p class="First">3</p> </td>          <td class="Toprule"> <p class="First">4</p> </td>          <td class="Toprule"> <p class="First">4</p> </td>          <td class="Toprule"> <p class="First">10</p> </td>          </tr>          <tr>           <td> <p class="First">LDL Cholesterol<br />*(Increase ≥ 50 mg/dl and an absolute value of ≥ 190 mg/dl)</p> </td>          <td> <p class="First">0</p> </td>          <td> <p class="First">1</p> </td>          <td> <p class="First">0</p> </td>          <td> <p class="First">1</p> </td>          <td> <p class="First">2</p> </td>          </tr>          <tr class="Last">           <td class="Botrule"> <p class="First">Triglycerides, fasting<br />*(Fasting: ≥ 327 mg/dl)</p> </td>          <td class="Botrule"> <p class="First">3</p> </td>          <td class="Botrule"> <p class="First">2</p> </td>          <td class="Botrule"> <p class="First">1</p> </td>          <td class="Botrule"> <p class="First">4</p> </td>          <td class="Botrule"> <p class="First">6</p> </td>          </tr>         </tbody>        </table>      </div>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="ID_260f2f8d-e6f1-4e65-9f41-ceee5014afb8"></a>      <a name="section-6.1.5.1.2"></a>       <p></p>       <p class="First"> <span class="Bold"><span class="Italics">Proteinuria</span></span> </p>       <p>Proteinuria, greater than or equal to trace, was observed in the pre-marketing fixed-dose controlled studies (see <a href="#_Reftable5">Table 5</a>). This proteinuria was not associated with increases in BUN or creatinine and was generally transient. </p>       <a name="_Reftable5"></a>       <div class="scrollingtable">       <table width="80%">         <caption>          <span>Table 5: Incidence (%) of Patients with Proteinuria in the Fixed-dose Clinical Studies</span>         </caption>         <colgroup>         <col width="19%" />          <col width="15%" />          <col width="15%" />          <col width="15%" />          <col width="15%" />          <col width="15%" />         </colgroup>        <thead>          <tr class="First">           <th class="Toprule" align="left" valign="top"></th>          <th class="Toprule" align="left" valign="top"></th>          <th class="Botrule Toprule" align="left" colspan="4" valign="top"><span class="Bold">PRISTIQ</span></th>          </tr>          <tr class="Last">           <th class="Botrule" align="left" valign="top"></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">Placebo</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">50 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">100 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">200 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">400 mg</span></th>          </tr>         </thead>         <tbody>          <tr class="First Last">           <td class="Botrule Toprule"> <p class="First">Proteinuria</p> </td>          <td class="Botrule Toprule"> <p class="First">4</p> </td>          <td class="Botrule Toprule"> <p class="First">6</p> </td>          <td class="Botrule Toprule"> <p class="First">8</p> </td>          <td class="Botrule Toprule"> <p class="First">5</p> </td>          <td class="Botrule Toprule"> <p class="First">7</p> </td>          </tr>         </tbody>        </table>      </div>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="ID_c7be2581-e674-4204-b95b-1b7e29b524cb"></a>      <a name="section-6.1.5.1.3"></a>       <p></p>       <p class="First"> <span class="Bold"><span class="Italics">Vital sign changes</span></span> </p>       <p>Table 6 summarizes the changes that were observed in placebo-controlled, short-term, pre-marketing studies with PRISTIQ in patients with MDD (doses 50 to 400 mg). </p>       <a name="_Reftable6"></a>       <div class="scrollingtable">       <table width="80%">         <caption>          <span>Table 6: Mean Changes in Vital Signs at Final on Therapy for All Short-term, Fixed-dose Controlled Studies</span>         </caption>         <colgroup>         <col width="19%" />          <col width="15%" />          <col width="15%" />          <col width="15%" />          <col width="15%" />          <col width="15%" />         </colgroup>        <thead>          <tr class="First">           <th class="Toprule" align="left" valign="top"></th>          <th class="Toprule" align="left" valign="top"></th>          <th class="Botrule Toprule" align="left" colspan="4" valign="top"><span class="Bold">PRISTIQ</span></th>          </tr>          <tr class="Last">           <th class="Botrule" align="left" valign="top"></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">Placebo</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">50 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">100 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">200 mg</span></th>          <th class="Botrule" align="left" valign="top"><span class="Bold">400 mg</span></th>          </tr>         </thead>         <tbody>          <tr class="First">           <td class="Toprule" colspan="6"> <p class="First"> <span class="Bold">Blood pressure</span> </p> </td>          </tr>          <tr>           <td> <p class="First">Supine systolic bp (mm Hg)</p> </td>          <td> <p class="First">-1.4</p> </td>          <td> <p class="First">1.2</p> </td>          <td> <p class="First">2.0</p> </td>          <td> <p class="First">2.5</p> </td>          <td> <p class="First">2.1</p> </td>          </tr>          <tr>           <td> <p class="First">Supine diastolic bp (mm Hg)</p> </td>          <td> <p class="First">-0.6</p> </td>          <td> <p class="First">0.7</p> </td>          <td> <p class="First">0.8</p> </td>          <td> <p class="First">1.8</p> </td>          <td> <p class="First">2.3</p> </td>          </tr>          <tr>           <td colspan="6"> <p class="First"> <span class="Bold">Pulse rate</span> </p> </td>          </tr>          <tr>           <td> <p class="First">Supine pulse (bpm)</p> </td>          <td> <p class="First">-0.3</p> </td>          <td> <p class="First">1.3</p> </td>          <td> <p class="First">1.3</p> </td>          <td> <p class="First">0.9</p> </td>          <td> <p class="First">4.1</p> </td>          </tr>          <tr class="Last">           <td class="Botrule"> <p class="First"> <span class="Bold">Weight (kg)</span> </p> </td>          <td class="Botrule"> <p class="First">0.0</p> </td>          <td class="Botrule"> <p class="First">-0.4</p> </td>          <td class="Botrule"> <p class="First">-0.6</p> </td>          <td class="Botrule"> <p class="First">-0.9</p> </td>          <td class="Botrule"> <p class="First">-1.1</p> </td>          </tr>         </tbody>        </table>      </div>       <p>Treatment with PRISTIQ at all doses from 50 mg per day to 400 mg per day in controlled studies was associated with sustained hypertension, defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥90 mm Hg and ≥10 mm Hg above baseline for 3 consecutive on-therapy visits (see <a href="#_Reftable7">Table 7</a>). Analyses of patients in PRISTIQ pre-marketing short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension. This was seen at all doses with a suggestion of a higher rate at 400 mg per day. </p>       <a name="_Reftable7"></a>       <div class="scrollingtable">       <table width="80%">         <caption>          <span>Table 7: Proportion of Patients with Sustained Elevation of Supine Diastolic Blood Pressure </span>         </caption>         <colgroup>         <col width="37%" />          <col width="55%" />         </colgroup>        <thead>          <tr class="First Last">           <th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Treatment Group</span></th>          <th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Proportion of Patients with Sustained Hypertension</span></th>          </tr>         </thead>         <tbody>          <tr class="First">           <td class="Toprule"> <p class="First">Placebo</p> </td>          <td class="Toprule"> <p class="First">0.5%</p> </td>          </tr>          <tr>           <td> <p class="First">PRISTIQ 50 mg per day </p> </td>          <td> <p class="First">1.3%</p> </td>          </tr>          <tr>           <td> <p class="First">PRISTIQ 100 mg per day </p> </td>          <td> <p class="First">0.7%</p> </td>          </tr>          <tr>           <td> <p class="First">PRISTIQ 200 mg per day </p> </td>          <td> <p class="First">1.1%</p> </td>          </tr>          <tr class="Last">           <td class="Botrule"> <p class="First">PRISTIQ 400 mg per day </p> </td>          <td class="Botrule"> <p class="First">2.3%</p> </td>          </tr>         </tbody>        </table>      </div>      </div>      <div class="Section" data-sectioncode="42229-5">       <a name="ID_c011b8e2-153b-4193-9b99-7dd6e0d799ba"></a>      <a name="section-6.1.5.1.4"></a>       <p></p>       <p class="First"> <span class="Bold"><span class="Italics">Orthostatic hypotension</span></span> </p>       <p>In the pre-marketing short-term, placebo-controlled clinical studies with doses of 50 to 400 mg, systolic orthostatic hypotension (decrease ≥30 mm Hg from supine to standing position) occurred more frequently in patients ≥65 years of age receiving PRISTIQ (8%, 7/87) versus placebo (2.5%, 1/40), compared to patients &lt;65 years of age receiving PRISTIQ (0.9%, 18/1,937) versus placebo (0.7%, 8/1,218).</p>      </div>     </div>    </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S6.2"></a>   <a name="section-6.2"></a>    <p></p>    <h2>6.2 Postmarketing Experience</h2>    <p class="First">The following adverse reaction has been identified during post-approval use of PRISTIQ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: </p>    <p> <span class="Bold"><span class="Italics">Skin and subcutaneous tissue disorders</span></span> – Stevens-Johnson syndrome.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">7 DRUG INTERACTIONS</a> <div class="Section toggle-content closed" data-sectioncode="34073-7">   <a name="S7"></a>  <a name="section-7"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S7.1"></a>   <a name="section-7.1"></a>    <p></p>    <h2>7.1 Monoamine Oxidase Inhibitors (MAOI) </h2>    <p class="First">Do not use MAOIs intended to treat psychiatric disorders with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine. Do not use desvenlafaxine within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start desvenlafaxine in a patient who is being treated with linezolid or intravenous methylene blue <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6 )</a>, <a href="#S4">Contraindications (4)</a> and <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.2"></a>   <a name="section-7.2"></a>    <p></p>    <h2>7.2 Serotonergic Drugs</h2>    <p class="First">Based on the mechanism of action of desvenlafaxine and the potential for serotonin syndrome, caution is advised when desvenlafaxine is co-administered with other drugs that may affect the serotonergic neurotransmitter systems <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>, <a href="#S4">Contraindications (4)</a> and <a href="#S5.2">Warnings and Precautions (5.2)</a>].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.3"></a>   <a name="section-7.3"></a>    <p></p>    <h2>7.3 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) </h2>    <p class="First">Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are co-administered with warfarin. Patients receiving warfarin therapy should be carefully monitored when PRISTIQ is initiated or discontinued <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.4"></a>   <a name="section-7.4"></a>    <p></p>    <h2>7.4 Potential for Other Drugs to Affect Desvenlafaxine </h2>    <p class="First">Based on <span class="Italics">in vitro</span> data, no dose adjustment is required for PRISTIQ when used concomitantly with inhibitors of CYP3A4 and CYP1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, 2E1, and the P-glycoprotein transporter. Clinical studies have demonstrated no clinically significant pharmacokinetic interaction between PRISTIQ and strong CYP 3A4 inhibitors (Figure 1). </p>    <div class="Figure">     <a name="id1925"></a>    <img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=image%2D01%2Ejpg" alt="Figure 1" />   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.5"></a>   <a name="section-7.5"></a>    <p></p>    <h2>7.5 Potential for Desvenlafaxine to Affect Other Drugs </h2>    <p class="First">Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily (Figure 2). Substrates primarily metabolized by CYP2D6 (e.g., desipramine , atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine) should be dosed at the original level when co-administered with PRISTIQ 100 mg or lower or when PRISTIQ is discontinued. Reduce the dose of these substrates by up to one-half if co-administered with 400 mg of PRISTIQ. </p>    <p>No additional dose adjustment is required for concomitant use of substrates of CYP3A4, 1A2, 2A6, 2C8, 2C9, and 2C19 isozymes, and P-glycoprotein transporter. Clinical studies have demonstrated no clinically significant pharmacokinetic interaction between PRISTIQ and CYP3A4 substrates (Figure 2). </p>    <p>Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).</p>    <p> <span class="Italics">In vitro</span> studies showed minimal inhibitory effect of desvenlafaxine on the CYP2D6 isoenzyme.</p>    <p> <span class="Italics">In vitro</span>, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. </p>    <p> <span class="Italics">In vitro</span>, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19, isozymes, and P-glycoprotein transporter and would not be expected to affect the pharmacokinetics of drugs that are substrates of these CYP isozymes and transporter.</p>    <div class="Figure">     <a name="id1949"></a>    <img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=pristiq%2D02%2Ejpg" alt="Figure 2" />   </div>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.6"></a>   <a name="section-7.6"></a>    <p></p>    <h2>7.6 Other Drugs Containing Desvenlafaxine or Venlafaxine</h2>    <p class="First">Avoid use of PRISTIQ with other desvenlafaxine-containing products or venlafaxine products. The concomitant use of PRISTIQ with other desvenlafaxine-containing products or venlafaxine will increase desvenlafaxine blood levels and increase dose-related adverse reactions <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>].</span> </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S7.7"></a>   <a name="section-7.7"></a>    <p></p>    <h2>7.7 Ethanol </h2>    <p class="First">A clinical study has shown that PRISTIQ does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking PRISTIQ. </p>   </div>   <div class="Section" data-sectioncode="34074-5">    <a name="S7.8"></a>   <a name="section-7.8"></a>    <p></p>    <h2>7.8 Drug-Laboratory Test Interactions</h2>    <p class="First">False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of desvenlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">8 USE IN SPECIFIC POPULATIONS</a> <div class="Section toggle-content closed" data-sectioncode="43684-0">   <a name="S8"></a>  <a name="section-8"></a>   <p></p>    <div class="Section" data-sectioncode="42228-7">    <a name="S8.1"></a>   <a name="section-8.1"></a>    <p></p>    <h2>8.1 Pregnancy</h2>    <div class="Section" data-sectioncode="34077-8">     <a name="ID_650680a3-6762-488d-85b3-355d4ffcf046"></a>    <a name="section-8.1.1"></a>     <p></p>     <p class="First"> <span class="Bold"><span class="Underline">Pregnancy Category C</span></span> </p>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_07733cae-26e4-4a46-a5af-9f9f43935ad5"></a>     <a name="section-8.1.1.1"></a>      <p></p>      <p class="First"> <span class="Italics">Risk summary</span> </p>      <p>There are no adequate and well-controlled studies of PRISTIQ in pregnant women. In reproductive developmental studies in rats and rabbits with desvenlafaxine succinate, evidence of teratogenicity was not observed at doses up to 30 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis) in rats, and up to 15 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis) in rabbits. An increase in rat pup deaths was seen during the first 4 days of lactation when dosing occurred during gestation and lactation, at doses greater than 10 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis). PRISTIQ should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_19d9f4e2-61c6-40c6-9914-c22ee1030496"></a>     <a name="section-8.1.1.2"></a>      <p></p>      <p class="First"> <span class="Italics">Clinical considerations</span> </p>      <p>A prospective longitudinal study of 201 women with history of major depression who were euthymic at the beginning of pregnancy, showed women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_d2a27d11-4157-4353-9c99-4a117f6e2a04"></a>     <a name="section-8.1.1.3"></a>      <p></p>      <p class="First"> <span class="Italics">Human data</span> </p>      <p>Neonates exposed to SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_6f2abe2b-a693-4592-a1b5-c412127e4bbc"></a>     <a name="section-8.1.1.4"></a>      <p></p>      <p class="First"> <span class="Italics">Animal data</span> </p>      <p>When desvenlafaxine succinate was administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 300 mg/kg/day and 75 mg/kg/day, respectively, no teratogenic effects were observed. These doses are 30 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis) in rats and 15 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis) in rabbits. However, fetal weights were decreased and skeletal ossification was delayed in rats in association with maternal toxicity at the highest dose, with a no-effect dose 10 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis).</p>      <p>When desvenlafaxine succinate was administered orally to pregnant rats throughout gestation and lactation, there was a decrease in pup weights and an increase in pup deaths during the first four days of lactation at the highest dose of 300 mg/kg/day. The cause of these deaths is not known. The no-effect dose for rat pup mortality was 10 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis). Post-weaning growth and reproductive performance of the progeny were not affected by maternal treatment with desvenlafaxine succinate at a dose 30 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis). </p>     </div>    </div>   </div>   <div class="Section" data-sectioncode="34080-2">    <a name="S8.3"></a>   <a name="section-8.2"></a>    <p></p>    <h2>8.3 Nursing Mothers</h2>    <p class="First">Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from PRISTIQ, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>   </div>   <div class="Section" data-sectioncode="34081-0">    <a name="S8.4"></a>   <a name="section-8.3"></a>    <p></p>    <h2>8.4 Pediatric Use</h2>    <p class="First">Safety and effectiveness in pediatric patients have not been established <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>. Anyone considering the use of PRISTIQ in a child or adolescent must balance the potential risks with the clinical need. </p>   </div>   <div class="Section" data-sectioncode="34082-8">    <a name="S8.5"></a>   <a name="section-8.4"></a>    <p></p>    <h2>8.5 Geriatric Use</h2>    <p class="First">Of the 4,158 patients in pre-marketing clinical studies with PRISTIQ, 6% were 65 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients; however, in the short-term placebo-controlled studies, there was a higher incidence of systolic orthostatic hypotension in patients ≥65 years of age compared to patients &lt;65 years of age treated with PRISTIQ <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>]</span>. For elderly patients, possible reduced renal clearance of PRISTIQ should be considered when determining dose <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>    <p>SSRIs and SNRIs, including PRISTIQ, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S8.6"></a>   <a name="section-8.5"></a>    <p></p>    <h2>8.6 Other Patient Factors </h2>    <p class="First">The effect of intrinsic patient factors on the pharmacokinetics of PRISTIQ is presented in Figure 3. </p>    <div class="Figure">     <a name="id2116"></a>    <img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=pristiq%2D03%2Ejpg" alt="Figure 3" />   </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_953d0d7a-8147-4c63-ae4c-4ec6165e1d25"></a>    <a name="section-8.5.1"></a>     <p></p>     <p class="First"> <span class="Underline">Renal Impairment:</span> </p>     <p>In subjects with renal impairment the clearance of PRISTIQ was decreased. In subjects with severe renal impairment (24-hr CrCl &lt;30 mL/min, Cockcroft-Gault) and end-stage renal disease, elimination half-lives were significantly prolonged, increasing exposures to PRISTIQ; therefore, dosage adjustment is recommended in these patients <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_024b6738-8f0e-4132-804c-af092713511a"></a>    <a name="section-8.5.2"></a>     <p></p>     <p class="First"> <span class="Underline">Hepatic Impairment:</span> </p>     <p>The mean terminal half-life (t<span class="Sub">1/2</span>) changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively. The recommended dose in patients with moderate to severe hepatic impairment is 50 mg per day. Dose escalation above 100 mg per day is not recommended <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. </p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">9 DRUG ABUSE AND DEPENDENCE</a> <div class="Section toggle-content closed" data-sectioncode="42227-9">   <a name="S9"></a>  <a name="section-9"></a>   <p></p>    <div class="Section" data-sectioncode="34085-1">    <a name="S9.1"></a>   <a name="section-9.1"></a>    <p></p>    <h2>9.1 Controlled Substance</h2>    <p class="First">PRISTIQ is not a controlled substance. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">10 OVERDOSAGE</a> <div class="Section toggle-content closed" data-sectioncode="34088-5">   <a name="S10"></a>  <a name="section-10"></a>   <p></p>    <div class="Section" data-sectioncode="42229-5">    <a name="S10.1"></a>   <a name="section-10.1"></a>    <p></p>    <h2>10.1 Human Experience with Overdosage </h2>    <p class="First">There is limited clinical trial experience with desvenlafaxine succinate overdosage in humans. However, desvenlafaxine (PRISTIQ) is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of PRISTIQ) is presented below; the identical information can be found in the Overdosage section of the venlafaxine package insert. </p>    <p>In postmarketing experience, overdose with venlafaxine (the parent drug of PRISTIQ) has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdosage include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported. </p>    <p>Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="S10.2"></a>   <a name="section-10.2"></a>    <p></p>    <h2>10.2 Management of Overdosage </h2>    <p class="First">No specific antidotes for PRISTIQ are known. In managing over dosage, consider the possibility of multiple drug involvement. In case of overdose, call Poison Control Center at 1-800-222-1222 for latest recommendations.</p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">11 DESCRIPTION</a> <div class="Section toggle-content closed" data-sectioncode="34089-3">   <a name="S11"></a>  <a name="section-11"></a>   <p></p>    <p class="First">PRISTIQ is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for the treatment of MDD. Desvenlafaxine (O-desmethylvenlafaxine) is the major active metabolite of the antidepressant venlafaxine, a medication used to treat major depressive disorder. </p>   <p>Desvenlafaxine is designated <span class="Italics">RS</span>-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol and has the empirical formula of C<span class="Sub">16</span>H<span class="Sub">25</span>NO<span class="Sub">2</span> (free base) and C<span class="Sub">16</span>H<span class="Sub">25</span>NO<span class="Sub">2</span>∙C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">4</span>∙H<span class="Sub">2</span>O (succinate monohydrate). Desvenlafaxine succinate monohydrate has a molecular weight of 399.48. The structural formula is shown below. </p>   <div class="Figure">    <a name="id2213"></a>   <img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=pristiq%2D04%2Ejpg" alt="Chemical Structure" />  </div>   <p>Desvenlafaxine succinate is a white to off-white powder that is soluble in water. The solubility of desvenlafaxine succinate is pH dependent. Its octanol:aqueous system (at pH 7.0) partition coefficient is 0.21. </p>   <p>PRISTIQ is formulated as an extended-release tablet for once-a-day oral administration. </p>   <p>Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively. </p>   <p>Inactive ingredients for the 25 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate, a film coating which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxides.</p>   <p>Inactive ingredients for the 50 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxides.</p>   <p>Inactive ingredients for the 100 mg tablet consist of hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&amp;C yellow #6. </p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">12 CLINICAL PHARMACOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="34090-1">   <a name="S12"></a>  <a name="section-12"></a>   <p></p>    <div class="Section" data-sectioncode="43679-0">    <a name="S12.1"></a>   <a name="section-12.1"></a>    <p></p>    <h2>12.1 Mechanism of Action</h2>    <p class="First">The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).</p>   </div>   <div class="Section" data-sectioncode="43681-6">    <a name="S12.2"></a>   <a name="section-12.2"></a>    <p></p>    <h2>12.2 Pharmacodynamics</h2>    <p class="First">Desvenlafaxine lacked significant affinity for numerous receptors, including muscarinic-cholinergic, H<span class="Sub">1</span>-histaminergic, or α<span class="Sub">1</span>-adrenergic receptors <span class="Italics">in vitro</span>. Desvenlafaxine also lacked monoamine oxidase (MAO) inhibitory activity. </p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_04350235-ea2b-47c3-97b1-98901b746257"></a>    <a name="section-12.2.1"></a>     <p></p>     <p class="First"> <span class="Underline">ECG changes</span> </p>     <p>Electrocardiograms were obtained from 1,492 desvenlafaxine treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8 weeks. No clinically relevant differences were observed between desvenlafaxine treated and placebo-treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval.</p>    </div>   </div>   <div class="Section" data-sectioncode="43682-4">    <a name="S12.3"></a>   <a name="section-12.3"></a>    <p></p>    <h2>12.3 Pharmacokinetics</h2>    <p class="First">The single-dose pharmacokinetics of desvenlafaxine are linear and dose-proportional in a dose range of 50 to 600 mg per day. With once-daily dosing, steady-state plasma concentrations are achieved within approximately 4 to 5 days. At steady-state, multiple-dose accumulation of desvenlafaxine is linear and predictable from the single-dose pharmacokinetic profile.</p>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_0a8323c6-342e-4335-bc12-1869739ab380"></a>    <a name="section-12.3.1"></a>     <p></p>     <p class="First"> <span class="Bold"><span class="Underline">Absorption and distribution</span></span> </p>     <p>The absolute oral bioavailability of PRISTIQ after oral administration is about 80%.</p>     <p>A food-effect study involving administration of PRISTIQ to healthy subjects under fasting and fed conditions (high-fat meal, 800 to 1000 calories) indicated that desvenlafaxine C<span class="Sub">max</span> was increased about 16% in the fed state, while the AUCs were similar. This difference is not expected to be clinically significant; therefore, PRISTIQ can be taken without regard to meals <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>]</span>. </p>     <p>The plasma protein binding of desvenlafaxine is low (30%) and is independent of drug concentration. The desvenlafaxine volume of distribution at steady-state following intravenous administration is 3.4 L/kg, indicating distribution into nonvascular compartments. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_4b4ded12-9168-412a-a52f-0d907ebf8e7d"></a>    <a name="section-12.3.2"></a>     <p></p>     <p class="First"> <span class="Bold"><span class="Underline">Metabolism and elimination </span></span> </p>     <p>Desvenlafaxine is primarily metabolized by conjugation (mediated by UGT isoforms) and, to a minor extent, through oxidative metabolism. CYP3A4 is the cytochrome P450 isozyme mediating the oxidative metabolism (N-demethylation) of desvenlafaxine. The CYP2D6 metabolic pathway is not involved, and after administration of 100 mg, the pharmacokinetics of desvenlafaxine was similar in subjects with CYP2D6 poor and extensive metabolizer phenotype. Approximately 45% of desvenlafaxine is excreted unchanged in urine at 72 hours after oral administration. Approximately 19% of the administered dose is excreted as the glucuronide metabolite and &lt;5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_e5498f01-5190-4f8b-9652-972cd0e63fcb"></a>    <a name="section-12.3.3"></a>     <p></p>     <p class="First"> <span class="Bold"><span class="Underline">Drug interaction studies</span></span> </p>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_e4ca45e1-2068-4d2a-aa47-662f74eaafbb"></a>     <a name="section-12.3.3.1"></a>      <p></p>      <p class="First"> <span class="Italics">Inhibitors of CYP3A4 (ketoconazole)</span> </p>      <p>CYP3A4 is a minor pathway for the metabolism of desvenlafaxine. In a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve (AUC) of desvenlafaxine (400 mg single dose) by about 43% and C<span class="Sub">max</span> by about 8%. Concomitant use of desvenlafaxine with potent inhibitors of CYP3A4 may result in higher concentrations of desvenlafaxine. </p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_eae1c063-aa97-4736-bbc0-bfc35f85456d"></a>     <a name="section-12.3.3.2"></a>      <p></p>      <p class="First"> <span class="Italics">Inhibitors of other CYP enzymes</span> </p>      <p>Based on in vitro data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of desvenlafaxine. </p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_eee44c1e-4940-4c70-be3f-888eacd6abbf"></a>     <a name="section-12.3.3.3"></a>      <p></p>      <p class="First"> <span class="Italics">Drugs metabolized by CYP2D6 (e.g. desipramine, dextromethorphan, metoprolol, atomoxetine) </span> </p>      <p>In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the C<span class="Sub">max</span> and AUC of desipramine increased approximately 25% and 17%, respectively. When 400 mg (8 times the recommended 50 mg dose) was administered, the C<span class="Sub">max</span> and AUC of desipramine increased approximately 50% and 90%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug <span class="Italics">[see <a href="#S7.5">Drug Interactions (7.5)</a>].</span> </p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_965766f1-c3d3-4dfd-8da3-6ab1cc82e4cc"></a>     <a name="section-12.3.3.4"></a>      <p></p>      <p class="First"> <span class="Italics">Drugs metabolized by CYP3A4 (midazolam) </span> </p>      <p>In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. In a clinical study, desvenlafaxine 400 mg daily (8 times the recommended 50 mg dose) was co-administered with a single 4 mg dose of midazolam (a CYP3A4 substrate). The AUC and C<span class="Sub">max</span> of midazolam decreased by approximately 31% and 16%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP3A4 can result in lower exposures to that drug. </p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_6c08f6e2-459d-4399-adf5-27b8aba2a275"></a>     <a name="section-12.3.3.5"></a>      <p></p>      <p class="First"> <span class="Italics">Drugs metabolized by CYP1A2, 2A6, 2C8, 2C9 and 2C19 </span> </p>      <p>In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes and would not be expected to affect the pharmacokinetics of drugs that are metabolized by these CYP isozymes. </p>      <p>In vitro, desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein transporter. The pharmacokinetics of desvenlafaxine are unlikely to be affected by drugs that inhibit the P-glycoprotein transporter, and desvenlafaxine is not likely to affect the pharmacokinetics of drugs that are substrates of the P-glycoprotein transporter. </p>     </div>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_919fa5dc-5036-4e92-abd7-62ddf39cee07"></a>    <a name="section-12.3.4"></a>     <p></p>     <p class="First"> <span class="Bold"><span class="Underline">Special populations</span></span> </p>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_aca92ea4-4354-4873-9e84-c069f5ee79f0"></a>     <a name="section-12.3.4.1"></a>      <p></p>      <p class="First"> <span class="Bold"><span class="Italics">Age</span></span> </p>      <p>In a study of healthy subjects administered doses of up to 300 mg, there was an approximate 32% increase in C<span class="Sub">max</span> and a 55% increase in AUC in subjects older than 75 years of age (n = 17), compared with subjects 18 to 45 years of age (n = 16). Subjects 65 to 75 years of age (n = 15) had no change in C<span class="Sub">max</span>, but an approximately 32% increase in AUC, compared to subjects 18 to 45 years of age <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>. </p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_7e3bd47c-eb41-42f8-8259-430fe2e6dd84"></a>     <a name="section-12.3.4.2"></a>      <p></p>      <p class="First"> <span class="Bold"><span class="Italics">Gender</span></span> </p>      <p>In a study of healthy subjects administered doses of up to 300 mg, women had an approximately 25% higher C<span class="Sub">max</span> and an approximately 10% higher AUC than age-matched men. No adjustment of dosage on the basis of gender is needed. </p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_a6879f34-55e8-4e76-9d7d-5d3019949717"></a>     <a name="section-12.3.4.3"></a>      <p></p>      <p class="First"> <span class="Bold"><span class="Italics">Race</span></span> </p>      <p>Pharmacokinetic analysis showed that race (White, n = 466; Black, n = 97; Hispanic, n = 39; Other, n = 33) had no apparent effect on the pharmacokinetics of PRISTIQ. No adjustment of dosage on the basis of race is needed. </p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_5bf3cc3a-c2a4-4dd8-b274-219bf025745a"></a>     <a name="section-12.3.4.4"></a>      <p></p>      <p class="First"> <span class="Bold"><span class="Italics">Hepatic insufficiency</span></span> </p>      <p>The disposition of desvenlafaxine succinate after administration of 100 mg was studied in subjects with mild (Child-Pugh A, n = 8), moderate (Child-Pugh B, n = 8), and severe (Child-Pugh C, n = 8) hepatic impairment and to healthy subjects (n = 12). </p>      <p>Average AUC was increased by approximately 31% and 35% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects. Average AUC values were similar in subjects with mild hepatic impairment and healthy subjects (&lt; 5% difference). </p>      <p>Systemic clearance (CL/F) was decreased by approximately 20% and 36% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects. CL/F values were comparable in mild hepatic impairment and healthy subjects (&lt; 5% difference). </p>      <p>The mean t<span class="Sub">1/2</span> changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively. The recommended dose in patients with hepatic impairment is 50 mg per day. Dose escalation above 100 mg per day is not recommended <span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>. </p>     </div>     <div class="Section" data-sectioncode="42229-5">      <a name="ID_cb4f3488-c603-4983-b284-49e6578bdcbd"></a>     <a name="section-12.3.4.5"></a>      <p></p>      <p class="First"> <span class="Bold"><span class="Italics">Renal insufficiency</span></span> </p>      <p>The disposition of desvenlafaxine after administration of 100 mg was studied in subjects with mild (n = 9), moderate (n = 8), severe (n = 7) and end-stage renal disease (ESRD) (n = 9) requiring dialysis and in healthy, age-matched control subjects (n = 8). Elimination was significantly correlated with creatinine clearance. Increases in AUCs of about 42% in mild renal impairment (24-hr CrCl = 50 to 80 mL/min, Cockcroft-Gault [C-G]), about 56% in moderate renal impairment (24-hr CrCl = 30 to 50 mL/min, C-G), about 108% in severe renal impairment (24-hr CrCl ≤30 mL/min, C-G), and about 116% in ESRD subjects were observed, compared with healthy, age-matched control subjects. </p>      <p>The mean terminal half-life (t<span class="Sub">1/2</span>) was prolonged from 11.1 hours in the control subjects to approximately 13.5, 15.5, 17.6, and 22.8 hours in mild, moderate, severe renal impairment and ESRD subjects, respectively. Less than 5% of the drug in the body was cleared during a standard 4-hour hemodialysis procedure. </p>      <p>The maximum recommended dose in patients with moderate renal impairment is 50 mg per day. Dosage adjustment of 50 mg every other day is recommended in patients with severe renal impairment or ESRD. [<span class="Italics">see <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a></span>]. </p>     </div>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">13 NONCLINICAL TOXICOLOGY</a> <div class="Section toggle-content closed" data-sectioncode="43680-8">   <a name="S13"></a>  <a name="section-13"></a>   <p></p>    <div class="Section" data-sectioncode="34083-6">    <a name="S13.1"></a>   <a name="section-13.1"></a>    <p></p>    <h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_e899bc02-5370-4e9b-8874-db2299baf9c8"></a>    <a name="section-13.1.1"></a>     <p></p>     <p class="First"> <span class="Underline">Carcinogenesis</span> </p>     <p>Desvenlafaxine succinate administered by oral gavage to mice and rats for 2 years did not increase the incidence of tumors in either study. </p>     <p>Mice received desvenlafaxine succinate at dosages up to 500/300 mg/kg/day (dosage lowered after 45 weeks of dosing). The 300 mg/kg/day dose is 15 times a human dose of 100 mg per day on a mg/m<span class="Sup">2</span> basis. </p>     <p>Rats received desvenlafaxine succinate at dosages up to 300 mg/kg/day (males) or 500 mg/kg/day (females). The highest dose is 29 (males) or 48 (females) times a human dose of 100 mg per day on a mg/m<span class="Sup">2</span> basis. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_ac2a7412-f717-4726-9d2b-d5ef3fd4e2fa"></a>    <a name="section-13.1.2"></a>     <p></p>     <p class="First"> <span class="Underline">Mutagenesis</span> </p>     <p>Desvenlafaxine was not mutagenic in the <span class="Italics">in vitro</span> bacterial mutation assay (Ames test) and was not clastogenic in an <span class="Italics">in vitro</span> chromosome aberration assay in cultured CHO cells, an <span class="Italics">in vivo</span> mouse micronucleus assay, or an <span class="Italics">in vivo</span> chromosome aberration assay in rats. Additionally, desvenlafaxine was not genotoxic in the <span class="Italics">in vitro</span> CHO mammalian cell forward mutation assay and was negative in the <span class="Italics">in vitro</span> BALB/c-3T3 mouse embryo cell transformation assay. </p>    </div>    <div class="Section" data-sectioncode="42229-5">     <a name="ID_f6c856df-65c3-496e-9944-696707f74312"></a>    <a name="section-13.1.3"></a>     <p></p>     <p class="First"> <span class="Underline">Impairment of fertility</span> </p>     <p>When desvenlafaxine succinate was administered orally to male and female rats, fertility was reduced at the high dose of 300 mg/kg/day, which is 30 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis). There was no effect on fertility at 100 mg/kg/day, approximately 10 times a human dose of 100 mg per day (on a mg/m<span class="Sup">2</span> basis). </p>    </div>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">14 CLINICAL STUDIES</a> <div class="Section toggle-content closed" data-sectioncode="34092-7">   <a name="S14"></a>  <a name="section-14"></a>   <p></p>    <p class="First">The efficacy of PRISTIQ as a treatment for depression was established in four 8-week, randomized, double-blind, placebo-controlled, fixed-dose studies (at doses of 50 mg per day to 400 mg per day) in adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder. In the first study, patients received 100 mg (n = 114), 200 mg (n = 116), or 400 mg (n = 113) of PRISTIQ once daily, or placebo (n = 118). In a second study, patients received either 200 mg (n = 121) or 400 mg (n = 124) of PRISTIQ once daily, or placebo (n = 124). In two additional studies, patients received 50 mg (n = 150 and n = 164) or 100 mg (n = 147 and n = 158) of PRISTIQ once daily, or placebo (n = 150 and n = 161). </p>   <p>PRISTIQ showed superiority over placebo as measured by improvement in the 17-item Hamilton Rating Scale for Depression (HAM-D<span class="Sub">17</span>) total score in four studies and overall improvement, as measured by the Clinical Global Impressions Scale - Improvement (CGI-I), in three of the four studies. In studies directly comparing 50 mg per day and 100 mg per day there was no suggestion of a greater effect with the higher dose and adverse reactions and discontinuations were more frequent at higher doses [<span class="Italics">see <a href="#S2.1">Dosage and Administration (2.1)</a></span>].</p>   <a name="_Reftable8"></a>   <div class="scrollingtable">   <table width="80%">     <caption>      <span>Table 8: Primary Efficacy (HAM-D<span class="Sub">17</span>) Results for Short-term Studies</span>     </caption>     <colgroup>     <col width="8%" />      <col width="16%" />      <col width="15%" />      <col width="13%" />      <col width="13%" />      <col width="13%" />      <col width="13%" />     </colgroup>    <thead>      <tr class="First">       <th class="Toprule" align="left" valign="top"></th>      <th class="Toprule" align="left" valign="top"></th>      <th class="Toprule" align="left" valign="top"></th>      <th class="Botrule Toprule" align="left" colspan="4" valign="top"><span class="Bold">PRISTIQ</span></th>      </tr>      <tr class="Last">       <th class="Botrule" align="left" valign="top"><span class="Bold">Study No.</span></th>      <th class="Botrule" align="left" valign="top"><span class="Bold">Primary Endpoint: HAM-D<span class="Sub">17</span></span></th>      <th class="Botrule" align="left" valign="top"><span class="Bold">Placebo</span></th>      <th class="Botrule" align="left" valign="top"><span class="Bold">50 mg/day</span></th>      <th class="Botrule" align="left" valign="top"><span class="Bold">100 mg/day</span></th>      <th class="Botrule" align="left" valign="top"><span class="Bold">200 mg/day</span></th>      <th class="Botrule" align="left" valign="top"><span class="Bold">400 mg/day</span></th>      </tr>     </thead>     <tfoot>      <tr>       <td align="left" colspan="7">        <dl class="Footnote">         <dt>          <a href="#footnote-reference-1" name="footnote-1">*</a>         </dt>         <dd>         Standard deviation;        </dd>         <dt>          <a href="#footnote-reference-2" name="footnote-2">†</a>         </dt>         <dd>         Difference between least squares means at final evaluation, calculated as drug response minus placebo response; unadjusted 95% confidence intervals        </dd>         <dt>          <a href="#footnote-reference-3" name="footnote-3">‡</a>         </dt>         <dd>         Adjusted p-value &lt; 0.05;        </dd>        </dl> </td>      </tr>     </tfoot>     <tbody>      <tr class="First">       <td class="Toprule" rowspan="2"> <p class="First">1</p> </td>      <td class="Toprule"> <p class="First">Baseline Score (SD<a class="Sup" href="#footnote-1" name="footnote-reference-1">*</a>)</p> </td>      <td class="Toprule"> <p class="First">23.1 (2.5)</p> </td>      <td class="Toprule"></td>      <td class="Toprule"> <p class="First">23.2 (2.5)</p> </td>      <td class="Toprule"> <p class="First">22.9 (2.4)</p> </td>      <td class="Toprule"> <p class="First">23.0 (2.2)</p> </td>      </tr>      <tr>       <td> <p class="First">Difference from Placebo (95% CI <a class="Sup" href="#footnote-2" name="footnote-reference-2">†</a>)</p> </td>      <td></td>      <td></td>      <td> <p class="First">-2.9<a class="Sup" href="#footnote-3" name="footnote-reference-3">‡</a> <br />(-5.1, -0.8)</p> </td>      <td> <p class="First">-2.0<br /> <br /> </p> </td>      <td> <p class="First">-3.1<a class="Sup" href="#footnote-3">‡</a> <br />(-5.2, -0.9)</p> </td>      </tr>      <tr>       <td rowspan="2"> <p class="First">2<br /> <br /> <br /> <br /> </p> </td>      <td> <p class="First">Baseline Score (SD<a class="Sup" href="#footnote-1">*</a>)</p> </td>      <td> <p class="First">25.3 (3.3)</p> </td>      <td></td>      <td></td>      <td> <p class="First">24.8 (2.9)</p> </td>      <td> <p class="First">25.2 (3.2)</p> </td>      </tr>      <tr>       <td> <p class="First">Difference from Placebo (95% CI <a class="Sup" href="#footnote-2">†</a>)</p> </td>      <td></td>      <td></td>      <td></td>      <td> <p class="First">-3.3<a class="Sup" href="#footnote-3">‡</a> <br />(-5.3, -1.2)</p> </td>      <td> <p class="First">-2.8<a class="Sup" href="#footnote-3">‡</a> <br />(-4.8, -0.7)</p> </td>      </tr>      <tr>       <td rowspan="2"> <p class="First">3<br /> <br /> <br /> <br /> </p> </td>      <td> <p class="First">Baseline Score (SD<a class="Sup" href="#footnote-1">*</a>)</p> </td>      <td> <p class="First">23.0 (2.6)</p> </td>      <td> <p class="First">23.4 (2.6)</p> </td>      <td> <p class="First">23.4 (2.6)</p> </td>      <td></td>      <td></td>      </tr>      <tr>       <td> <p class="First">Difference from Placebo (95% CI <a class="Sup" href="#footnote-2">†</a>)</p> </td>      <td></td>      <td> <p class="First">-1.9<a class="Sup" href="#footnote-3">‡</a> <br />(-3.5, -0.3)</p> </td>      <td> <p class="First">-1.5<br /> </p> </td>      <td></td>      <td></td>      </tr>      <tr>       <td class="Botrule" rowspan="2"> <p class="First">4<br /> <br /> <br /> <br /> </p> </td>      <td> <p class="First">Baseline Score (SD<a class="Sup" href="#footnote-1">*</a>)</p> </td>      <td> <p class="First">24.3 (2.6)</p> </td>      <td> <p class="First">24.3 (2.4)</p> </td>      <td> <p class="First">24.4 (2.7)</p> </td>      <td></td>      <td></td>      </tr>      <tr class="Last">       <td class="Botrule"> <p class="First">Difference from Placebo (95% CI <a class="Sup" href="#footnote-2">†</a>)</p> </td>      <td class="Botrule"></td>      <td class="Botrule"> <p class="First">-2.5<a class="Sup" href="#footnote-3">‡</a> <br />(-4.1, -0.9)</p> </td>      <td class="Botrule"> <p class="First">-3.0<a class="Sup" href="#footnote-3">‡</a> <br />(-4.7, -1.4)</p> </td>      <td class="Botrule"></td>      <td class="Botrule"></td>      </tr>     </tbody>    </table>  </div>   <p>Analyses of the relationships between treatment outcome and age and treatment outcome and gender did not suggest any differential responsiveness on the basis of these patient characteristics. There was insufficient information to determine the effect of race on outcome in these studies.</p>   <p>In a longer-term trial (Study 5), adult outpatients meeting DSM-IV criteria for major depressive disorder, who responded to 8 weeks of open-label acute treatment with 50 mg per day desvenlafaxine and subsequently remained stable for 12 weeks on desvenlafaxine, were assigned randomly in a double-blind manner to remain on active treatment or switch to placebo for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a HAM-D<span class="Sub">17</span> total score of ≤ 11 and CGI-I ≤ 2 at the day 56 evaluation; stability was defined as HAM-D<span class="Sub">17</span> total score of ≤ 11 and CGI-I ≤ 2 at week 20 and not having a HAM-D<span class="Sub">17</span> total score of ≥ 16 or a CGI-I score ≥ 4 at any office visit. Relapse during the double-blind phase was defined as follows: (1) a HAM-D<span class="Sub">17</span> total score of ≥ 16 at any office visit, (2) discontinuation for unsatisfactory efficacy response, (3) hospitalized for depression, (4) suicide attempt, or (5) suicide. Patients receiving continued desvenlafaxine treatment experienced statistically significantly longer time to relapse compared with placebo. At 26 weeks, the Kaplan-Meier estimated proportion of relapse was 14% with desvenlafaxine treatment versus 30% with placebo.</p>   <div class="scrollingtable">   <table width="75%">     <colgroup>     <col width="87%" />     </colgroup>    <tbody class="Headless">      <tr class="First">       <td class="Toprule"> <p class="First"> <span class="Bold">Figure 4. Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5)</span> </p> </td>      </tr>      <tr class="Last">       <td class="Botrule"><a name="id2638"></a><img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=pristiq%2D05%2Ejpg" alt="Figure 4" /></td>      </tr>     </tbody>    </table>  </div>   <p>In another longer-term trial (Study 6), adult outpatients meeting DSM-IV criteria for major depressive disorder and who responded to 12 weeks of acute treatment with desvenlafaxine were assigned randomly to the same dose (200 or 400 mg per day) they had received during acute treatment or to placebo for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a HAM-D<span class="Sub">17</span> total score of ≤ 11 at the day 84 evaluation. Relapse during the double-blind phase was defined as follows: (1) a HAM-D<span class="Sub">17</span> total score of ≥ 16 at any office visit, (2) a CGI-I score of ≥ 6 (versus day 84) at any office visit, or (3) discontinuation from the trial due to unsatisfactory response. Patients receiving continued desvenlafaxine treatment experienced statistically significantly longer time to relapse over the subsequent 26 weeks compared with those receiving placebo. At 26 weeks, the Kaplan-Meier estimated proportion of relapse was 29% with desvenlafaxine treatment versus 49% with placebo.</p>   <div class="scrollingtable">   <table width="75%">     <colgroup>     <col width="87%" />     </colgroup>    <tbody class="Headless">      <tr class="First">       <td class="Toprule"> <p class="First"> <span class="Bold">Figure 5. Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 6)</span> </p> </td>      </tr>      <tr class="Last">       <td class="Botrule"><a name="id2651"></a><img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=pristiq%2D06%2Ejpg" alt="Figure 5" /></td>      </tr>     </tbody>    </table>  </div>   <p>In a postmarketing study, the efficacy of PRISTIQ at a dose lower than 50 mg per day was evaluated in an 8-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study in adult outpatients with Major Depressive Disorder. The treatment arms were 25 mg (n=232), 50 mg (n=236), and placebo (n=231). The 50 mg dose was superior to placebo, as measured by the mean change from baseline on the HAMD-17. The 25 mg dose was not superior to placebo.</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a> <div class="Section toggle-content closed" data-sectioncode="34069-5">   <a name="S16"></a>  <a name="section-15"></a>   <p></p>    <p class="First">PRISTIQ (desvenlafaxine) Extended-Release Tablets are available as follows: </p>   <p> <span class="Bold">25 mg, tan, square pyramid tablet debossed with &quot;W&quot; (over) &quot;25&quot; on the flat side</span> </p>   <dl>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1210-30, bottle of 30 tablets in unit-of-use package   </dd>   </dl>   <p> <span class="Bold">50 mg, light pink, square pyramid tablet debossed with &quot;W&quot; (over) &quot;50&quot; on the flat side</span> </p>   <dl>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1211-14, bottle of 14 tablets in unit-of-use package   </dd>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1211-30, bottle of 30 tablets in unit-of-use package   </dd>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1211-01, bottle of 90 tablets in unit-of-use package   </dd>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1211-50, 10 blisters of 10 (HUD)   </dd>   </dl>   <p> <span class="Bold">100 mg, reddish-orange, square pyramid tablet debossed with &quot;W&quot; (over) &quot;100&quot; on the flat side</span> </p>   <dl>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1222-14, bottle of 14 tablets in unit-of-use package   </dd>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1222-30, bottle of 30 tablets in unit-of-use package   </dd>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1222-01, bottle of 90 tablets in unit-of-use package   </dd>    <dt>    &nbsp;   </dt>    <dd>    NDC 0008-1222-50, 10 blisters of 10 (HUD)   </dd>   </dl>   <div class="Section" data-sectioncode="44425-7">    <a name="ID_d86cc6c9-d61f-4d88-94fe-4ed889429ce9"></a>   <a name="section-15.1"></a>    <p></p>    <p class="First">Store at 20&deg; to 25&deg;C (68&deg; to 77&deg;F); excursions permitted to 15&deg; to 30&deg;C (59&deg; to 86&deg;F) <span class="Italics">[see USP Controlled Room Temperature]</span>. </p>    <p>Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively. </p>    <p>The unit-of-use package is intended to be dispensed as a unit.</p>    <p>The appearance of these tablets is a trademark of Wyeth Pharmaceuticals. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">17 PATIENT COUNSELING INFORMATION</a> <div class="Section toggle-content closed" data-sectioncode="34076-0">   <a name="S17"></a>  <a name="section-16"></a>   <p></p>    <p class="First">See FDA-approved patient labeling (<a href="#MG">Medication Guide</a>).</p>   <p>Advise patients, their families, and their caregivers about the benefits and risks associated with treatment with PRISTIQ and counsel them in its appropriate use. </p>   <p>Advise patients, their families, and their caregivers to read the Medication Guide and assist them in understanding its contents. The complete text of the Medication Guide is reprinted at the end of this document. </p>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_d345e8bb-73dd-481c-9a62-e861d5b53e04"></a>   <a name="section-16.1"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Suicide Risk </span></span> </p>    <p>Advise patients, their families and caregivers to look for the emergence of suicidality, especially early during treatment and when the dose is adjusted up or down <span class="Italics">[see <a href="#BOX">Boxed Warning</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_9e400d7c-083b-4944-b387-1273b5d1c629"></a>   <a name="section-16.2"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Concomitant Medication </span></span> </p>    <p>Advise patients taking PRISTIQ not to use concomitantly other products containing desvenlafaxine or venlafaxine. Healthcare professionals should instruct patients not to take PRISTIQ with an MAOI or within 14 days of stopping an MAOI and to allow 7 days after stopping PRISTIQ before starting an MAOI <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_771a0b17-1ada-4dad-89fd-add124eaa904"></a>   <a name="section-16.3"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Serotonin Syndrome </span></span> </p>    <p>Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of PRISTIQ with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort supplements) [<span class="Italics">see <a href="#S5.2">Warnings and Precautions (5.2)</a></span>]. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_a13533f7-dbae-4b9f-bedb-90175eb03940"></a>   <a name="section-16.4"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Elevated Blood Pressure </span></span> </p>    <p>Advise patients that they should have regular monitoring of blood pressure when taking PRISTIQ <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_3106fef5-1de3-41c0-9ff2-adc2ac9bc94e"></a>   <a name="section-16.5"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Abnormal Bleeding </span></span> </p>    <p>Patients should be cautioned about the concomitant use of PRISTIQ and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of bleeding <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_85f32476-a51d-4d03-87e1-05be04616051"></a>   <a name="section-16.6"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Angle Closure Glaucoma </span></span> </p>    <p>Patients should be advised that taking Pristiq can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle closure glaucoma, when diagnosed, can be treated definitively with iridectomy. Open-angle glaucoma is not a risk factor for angle closure glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible. [see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_1944a915-d7cf-44a9-a437-cfbd32ae53d9"></a>   <a name="section-16.7"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Activation of Mania/Hypomania </span></span> </p>    <p>Advise patients, their families and caregivers to observe for signs of activation of mania/hypomania <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_34e5b028-eae0-418d-8f8f-2c0582c76831"></a>   <a name="section-16.8"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Discontinuation </span></span> </p>    <p>Advise patients not to stop taking PRISTIQ without talking first with their healthcare professional. Patients should be aware that discontinuation effects may occur when stopping PRISTIQ, and a dose of 25 mg per day is available for discontinuing therapy <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a> and <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_c29c04b6-b672-443b-bbb0-2300b7f206e1"></a>   <a name="section-16.9"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Switching Patients From Other Antidepressants to PRISTIQ </span></span> </p>    <p>Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to PRISTIQ. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms.</p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_947c7511-739d-4f7f-8b8b-3bb4f0c385c9"></a>   <a name="section-16.10"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Interference with Cognitive and Motor Performance </span></span> </p>    <p>Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that PRISTIQ therapy does not adversely affect their ability to engage in such activities. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_83410c21-c3e4-4dd6-a369-a77eac3cc4c8"></a>   <a name="section-16.11"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Alcohol </span></span> </p>    <p>Advise patients to avoid alcohol while taking PRISTIQ <span class="Italics">[see <a href="#S7.7">Drug Interactions (7.7)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_c537ffce-3b36-4523-b3a4-89cadeca555b"></a>   <a name="section-16.12"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Allergic Reactions </span></span> </p>    <p>Advise patients to notify their physician if they develop allergic phenomena such as rash, hives, swelling, or difficulty breathing. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_1fd46ea7-64d4-4ff9-b0d0-20c3dda72965"></a>   <a name="section-16.13"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Pregnancy </span></span> </p>    <p>Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_94b45cf2-bddf-4fa6-9c7f-cf07c7e9215d"></a>   <a name="section-16.14"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Nursing </span></span> </p>    <p>Advise patients to notify their physician if they are breastfeeding an infant <span class="Italics">[see <a href="#S8.3">Use in Specific Populations (8.3)</a>]</span>. </p>   </div>   <div class="Section" data-sectioncode="42229-5">    <a name="ID_1c6e2ad5-6249-4b68-baf1-7564aca3ea50"></a>   <a name="section-16.15"></a>    <p></p>    <p class="First"> <span class="Bold"><span class="Underline">Residual Inert Matrix Tablet </span></span> </p>    <p>Patients receiving PRISTIQ may notice an inert matrix tablet passing in the stool or via colostomy. Patients should be informed that the active medication has already been absorbed by the time the patient sees the inert matrix tablet. </p>   </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">MEDICATION GUIDE</a> <div class="Section toggle-content closed" data-sectioncode="42231-1">   <a name="MG"></a>  <a name="section-17"></a>   <p></p>    <p class="First">PRISTIQ<span class="Sup">&reg;</span> (pris-<span class="Bold">TEEK</span>)<br />(desvenlafaxine)<br />Extended-Release Tablets</p>   <p>Read this Medication Guide before you start taking PRISTIQ and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. </p>   <p> <span class="Bold">Antidepressant Medicines, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts or Actions</span> </p>   <p> <span class="Bold">Talk to your healthcare provider about:</span> </p>   <dl>    <dt>    •   </dt>    <dd>    all risks and benefits of treatment with antidepressant medicines    </dd>    <dt>    •   </dt>    <dd>    all treatment choices for depression or other serious mental illness    </dd>   </dl>   <p> <span class="Bold">What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?</span> </p>   <dl>    <dt>    1.   </dt>    <dd>     <span class="Bold">Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.</span>    </dd>    <dt>    2.   </dt>    <dd>     <span class="Bold">Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. </span>These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.   </dd>    <dt>    3.   </dt>    <dd>     <span class="Bold">How can I watch for and try to prevent suicidal thoughts and actions?</span>     <dl>      <dt>      •     </dt>      <dd>      Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.      </dd>      <dt>      •     </dt>      <dd>      Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.      </dd>      <dt>      •     </dt>      <dd>      Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.      </dd>     </dl>    </dd>   </dl>   <p> <span class="Bold">Call a healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:</span> </p>   <div class="scrollingtable">   <table width="100%">     <colgroup>     <col width="50%" />      <col width="50%" />     </colgroup>    <tbody class="Headless">      <tr class="First Last">       <td class="Botrule Toprule">        <dl>         <dt>         •        </dt>         <dd>         thoughts about suicide or dying        </dd>         <dt>         •        </dt>         <dd>         attempts to commit suicide        </dd>         <dt>         •        </dt>         <dd>         new or worse depression        </dd>         <dt>         •        </dt>         <dd>         new or worse anxiety        </dd>         <dt>         •        </dt>         <dd>         feeling very agitated or restless        </dd>         <dt>         •        </dt>         <dd>         panic attacks        </dd>        </dl> </td>      <td class="Botrule Toprule">        <dl>         <dt>         •        </dt>         <dd>         trouble sleeping (insomnia)        </dd>         <dt>         •        </dt>         <dd>         new or worse irritability        </dd>         <dt>         •        </dt>         <dd>         acting aggressive, being angry, or violent        </dd>         <dt>         •        </dt>         <dd>         acting on dangerous impulses        </dd>         <dt>         •        </dt>         <dd>         an extreme increase in activity and talking (mania)        </dd>         <dt>         •        </dt>         <dd>         other unusual changes in behavior or mood        </dd>        </dl> </td>      </tr>     </tbody>    </table>  </div>   <p> <span class="Bold">What else do I need to know about antidepressant medicines?</span> </p>   <dl>    <dt>    •   </dt>    <dd>    Never stop an antidepressant medicine without first talking to a healthcare provider. Stopping an antidepressant medicine suddenly can cause other symptoms.    </dd>    <dt>    •   </dt>    <dd>     <span class="Bold">Antidepressants are medicines used to treat depression and other illnesses.</span> It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.    </dd>    <dt>    •   </dt>    <dd>     <span class="Bold">Antidepressant medicines have other side effects.</span> Talk to the healthcare provider about the side effects of this medicine.    </dd>    <dt>    •   </dt>    <dd>     <span class="Bold">Antidepressant medicines can interact with other medicines.</span> Know all of the medicines that you take. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.    </dd>    <dt>    •   </dt>    <dd>     <span class="Bold">Not all antidepressant medicines prescribed for children are FDA approved for use in children.</span> Talk to your child's healthcare provider for more information.    </dd>   </dl>   <p> <span class="Bold">Important Information about PRISTIQ Extended-Release Tablets</span> </p>   <p>Read the patient information that comes with PRISTIQ before you take PRISTIQ and each time you refill your prescription. There may be new information. If you have questions, ask your healthcare provider. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. </p>   <p> <span class="Bold">What is PRISTIQ?</span> </p>   <dl>    <dt>    •   </dt>    <dd>    PRISTIQ is a prescription medicine used to treat depression. PRISTIQ belongs to a class of medicines known as SNRIs (or serotonin-norepinephrine reuptake inhibitors).    </dd>   </dl>   <p> <span class="Bold">Who should not take PRISTIQ?</span> </p>   <p> <span class="Bold">Do not take PRISTIQ if you:</span> </p>   <dl>    <dt>    •   </dt>    <dd>    are allergic to desvenlafaxine, venlafaxine or any of the ingredients in PRISTIQ. See the end of this Medication Guide for a complete list of ingredients in PRISTIQ.   </dd>    <dt>    •   </dt>    <dd>    take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid and the intravenous medicine methylene blue.    </dd>    <dt>    •   </dt>    <dd>    have taken an MAOI within 7 days of stopping PRISTIQ unless directed by your healthcare provider.   </dd>    <dt>    •   </dt>    <dd>    have started PRISTIQ and if you stopped taking an MAOI in the last 14 days unless directed by your healthcare provider.   </dd>   </dl>   <p> <span class="Bold">What should I tell my healthcare provider before taking PRISTIQ?</span> </p>   <p>Tell your healthcare provider about all your medical conditions, including if you: </p>   <dl>    <dt>    •   </dt>    <dd>    have high blood pressure    </dd>    <dt>    •   </dt>    <dd>    have heart problems    </dd>    <dt>    •   </dt>    <dd>    have high cholesterol or high triglycerides    </dd>    <dt>    •   </dt>    <dd>    have a history of a stroke    </dd>    <dt>    •   </dt>    <dd>    have or had depression, suicidal thoughts or behavior   </dd>    <dt>    •   </dt>    <dd>    have kidney problems    </dd>    <dt>    •   </dt>    <dd>    have liver problems    </dd>    <dt>    •   </dt>    <dd>    have or had bleeding problems    </dd>    <dt>    •   </dt>    <dd>    have or had seizures or convulsions    </dd>    <dt>    •   </dt>    <dd>    have mania or bipolar disorder    </dd>    <dt>    •   </dt>    <dd>    have low sodium levels in your blood    </dd>    <dt>    •   </dt>    <dd>    are pregnant or plan to become pregnant. It is not known if PRISTIQ will harm your unborn baby.    </dd>    <dt>    •   </dt>    <dd>    are breastfeeding. PRISTIQ can pass into your breast milk and may harm your baby. Talk with your healthcare provider about the best way to feed your baby if you take PRISTIQ.    </dd>   </dl>   <p> <span class="Bold">Serotonin syndrome </span> </p>   <p>Rare, but potentially life-threatening conditions called serotonin syndrome can happen when medicines such as PRISTIQ are taken with certain other medicines. Serotonin syndrome can cause serious changes in how your brain, muscles, heart and blood vessels, and digestive system work. <span class="Bold">Especially tell your healthcare provider if you take the following:</span> </p>   <dl>    <dt>    •   </dt>    <dd>    medicines to treat migraine headaches known as triptans    </dd>    <dt>    •   </dt>    <dd>    medicines used to treat mood, anxiety, psychotic, or thought disorders, including tricyclics, lithium, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or other dopamine antagonists, such as metoclopramide   </dd>    <dt>    •   </dt>    <dd>    silbutramine    </dd>    <dt>    •   </dt>    <dd>    tramadol    </dd>    <dt>    •   </dt>    <dd>    St. John's Wort    </dd>    <dt>    •   </dt>    <dd>    MAOIs (including linezolid, an antibiotic and intravenous methylene blue)    </dd>    <dt>    •   </dt>    <dd>    tryptophan supplements    </dd>   </dl>   <p>Ask your healthcare provider if you are not sure if you are taking any of these medicines. </p>   <p>Before you take PRISTIQ with any of these medicines, talk to your healthcare provider about serotonin syndrome. See &quot;<a href="#_Refpossible">What are the possible side effects of PRISTIQ?</a>&quot; </p>   <p> <span class="Bold">Do not take PRISTIQ with other medicines containing venlafaxine or desvenlafaxine.</span> </p>   <p> <span class="Bold">How should I take PRISTIQ?</span> </p>   <dl>    <dt>    •   </dt>    <dd>    Take PRISTIQ exactly as your healthcare provider has told you.    </dd>    <dt>    •   </dt>    <dd>    Take PRISTIQ at about the same time each day.    </dd>    <dt>    •   </dt>    <dd>    PRISTIQ may be taken either with or without food.    </dd>    <dt>    •   </dt>    <dd>    Swallow PRISTIQ tablets whole, with fluid. Do not crush, cut, chew, or dissolve PRISTIQ tablets because the tablets are time-released.    </dd>    <dt>    •   </dt>    <dd>    When you take PRISTIQ, you may see something in your stool that looks like a tablet. This is the empty shell from the tablet after the medicine has been absorbed by your body.    </dd>    <dt>    •   </dt>    <dd>    It is common for antidepressant medicines such as PRISTIQ to take several weeks before you start to feel better. Do not stop taking PRISTIQ if you do not feel results right away.    </dd>    <dt>    •   </dt>    <dd>    Do not stop taking or change the dose of PRISTIQ without talking with your healthcare provider, even if you feel better.    </dd>    <dt>    •   </dt>    <dd>    Talk with your healthcare provider about how long you should use PRISTIQ. Take PRISTIQ for as long as your healthcare provider tells you to.    </dd>    <dt>    •   </dt>    <dd>    If you miss a dose of PRISTIQ, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not try to &quot;make up&quot; for the missed dose by taking two doses at the same time.    </dd>    <dt>    •   </dt>    <dd>    Do not take more PRISTIQ than prescribed by your healthcare provider. If you take more PRISTIQ than the amount prescribed, contact your healthcare provider right away.    </dd>    <dt>    •   </dt>    <dd>    If you take too much PRISTIQ, call the Poison Control Center at 1-800-222-1222 or go to the nearest hospital emergency room right away.    </dd>   </dl>   <p> <span class="Bold">Switching from other antidepressants</span> </p>   <p>Side effects from discontinuing antidepressant medication have occurred when patients switched from other antidepressants, including venlafaxine, to PRISTIQ. Your doctor may gradually reduce the dose of your initial antidepressant medication to help to reduce these side effects.</p>   <p> <span class="Bold">What should I avoid while taking PRISTIQ?</span> </p>   <dl>    <dt>    •   </dt>    <dd>    Do not drive a car or operate machinery until you know how PRISTIQ affects you.    </dd>    <dt>    •   </dt>    <dd>    Avoid drinking alcohol while taking PRISTIQ.    </dd>   </dl>   <p> <span class="Bold">What are the possible side effects of PRISTIQ?</span> </p>   <p> <span class="Bold">PRISTIQ can cause serious side effects, including:</span> </p>   <dl>    <dt>    •   </dt>    <dd>     <span class="Bold">See the beginning of this <a href="#_Refanti">Medication Guide -Antidepressant Medicines, Depression and other Serious Mental Illnesses, and Suicidal Thoughts or Actions</a>.</span>    </dd>    <dt>    •   </dt>    <dd>     <span class="Bold">Serotonin syndrome. See &quot;<a href="#_Refshould">What should I tell my healthcare provider before taking PRISTIQ?</a>&quot;</span>     <br />Get medical help right away if you think that you have these syndromes. Signs and symptoms of these syndromes may include one or more of the following:   </dd>   </dl>   <div class="scrollingtable">   <table width="100%">     <colgroup>     <col width="50%" />      <col width="50%" />     </colgroup>    <tbody class="Headless">      <tr class="First Last">       <td class="Botrule Toprule">        <dl>         <dt>         •        </dt>         <dd>         restlessness        </dd>         <dt>         •        </dt>         <dd>         hallucinations (seeing and hearing things that are not real)        </dd>         <dt>         •        </dt>         <dd>         loss of coordination        </dd>         <dt>         •        </dt>         <dd>         fast heart beat         </dd>         <dt>         •        </dt>         <dd>         increased body temperature        </dd>         <dt>         •        </dt>         <dd>         muscle stiffness        </dd>        </dl> </td>      <td class="Botrule Toprule">        <dl>         <dt>         •        </dt>         <dd>         increase in blood pressure         </dd>         <dt>         •        </dt>         <dd>         diarrhea        </dd>         <dt>         •        </dt>         <dd>         coma        </dd>         <dt>         •        </dt>         <dd>         nausea        </dd>         <dt>         •        </dt>         <dd>         vomiting        </dd>         <dt>         •        </dt>         <dd>         confusion        </dd>        </dl> </td>      </tr>     </tbody>    </table>  </div>   <p> <span class="Bold">PRISTIQ may also cause other serious side effects, including:</span> </p>   <dl>    <dt>    •   </dt>    <dd>     <span class="Bold">New or worsened high blood pressure (hypertension).</span> Your healthcare provider should monitor your blood pressure before and while you are taking PRISTIQ. If you have high blood pressure, it should be controlled before you start taking PRISTIQ.    </dd>    <dt>    •   </dt>    <dd>     <span class="Bold">Abnormal bleeding or bruising.</span> PRISTIQ and other SNRIs/SSRIs may cause you to have an increased chance of bleeding. Taking aspirin, NSAIDs (non-steroidal anti-inflammatory drugs), or blood thinners may add to this risk. Tell your healthcare provider right away about any unusual bleeding or bruising.    </dd>    <dt>    •   </dt>    <dd>     <span class="Bold">Visual problems</span>Only some people are at risk for these problems. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are.    <br />     <span class="Bold">Symptoms when stopping PRISTIQ (discontinuation symptoms).</span> Side effects may occur when stopping PRISTIQ (discontinuation symptoms), especially when therapy is stopped suddenly. Your healthcare provider may want to decrease your dose slowly to help avoid side effects. Some of these side effects may include:     <dl>      <dt>      •     </dt>      <dd>      eye pain     </dd>      <dt>      •     </dt>      <dd>      changes in vision     </dd>      <dt>      •     </dt>      <dd>      swelling or redness in or around the eye     </dd>     </dl>    </dd>   </dl>   <div class="scrollingtable">   <table width="100%">     <colgroup>     <col width="50%" />      <col width="50%" />     </colgroup>    <tbody class="Headless">      <tr class="First Last">       <td class="Botrule Toprule">        <dl>         <dt>         •        </dt>         <dd>         dizziness        </dd>         <dt>         •        </dt>         <dd>         nausea        </dd>         <dt>         •        </dt>         <dd>         headache        </dd>         <dt>         •        </dt>         <dd>         irritability        </dd>         <dt>         •        </dt>         <dd>         sleeping problems (insomnia)        </dd>        </dl> </td>      <td class="Botrule Toprule">        <dl>         <dt>         •        </dt>         <dd>         anxiety        </dd>         <dt>         •        </dt>         <dd>         abnormal dreams        </dd>         <dt>         •        </dt>         <dd>         tiredness        </dd>         <dt>         •        </dt>         <dd>         sweating        </dd>         <dt>         •        </dt>         <dd>         diarrhea        </dd>        </dl> </td>      </tr>     </tbody>    </table>  </div>   <p>Common side effects with PRISTIQ include: </p>   <div class="scrollingtable">   <table width="100%">     <colgroup>     <col width="50%" />      <col width="50%" />     </colgroup>    <tbody class="Headless">      <tr class="First Last">       <td class="Botrule Toprule">        <dl>         <dt>         •        </dt>         <dd>         nausea        </dd>         <dt>         •        </dt>         <dd>         dizziness        </dd>         <dt>         •        </dt>         <dd>         insomnia        </dd>         <dt>         •        </dt>         <dd>         sweating        </dd>         <dt>         •        </dt>         <dd>         constipation        </dd>        </dl> </td>      <td class="Botrule Toprule">        <dl>         <dt>         •        </dt>         <dd>         sleepiness        </dd>         <dt>         •        </dt>         <dd>         loss of appetite        </dd>         <dt>         •        </dt>         <dd>         anxiety        </dd>         <dt>         •        </dt>         <dd>         decreased sex drive        </dd>         <dt>         •        </dt>         <dd>         delayed orgasm and ejaculation        </dd>        </dl> </td>      </tr>     </tbody>    </table>  </div>   <p>These are not all the possible side effects of PRISTIQ. Tell your healthcare provider about any side effect that bothers you or does not go away. </p>   <p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>   <p> <span class="Bold">How should I store PRISTIQ?</span> </p>   <dl>    <dt>    •   </dt>    <dd>    Store PRISTIQ at 68&deg;F to 77&deg;F (20&deg;C to 25&deg;C).    </dd>    <dt>    •   </dt>    <dd>    Do not use PRISTIQ after the expiration date (EXP), which is on the container. The expiration date refers to the last day of that month.    </dd>    <dt>    •   </dt>    <dd>    Keep PRISTIQ and all medicines out of the reach of children.    </dd>   </dl>   <p> <span class="Bold">General Information about the safe and effective use of PRISTIQ</span> </p>   <p>Medicines are sometimes used for conditions that are not mentioned in Medication Guides. Do not use PRISTIQ for a condition for which it was not prescribed. Do not give PRISTIQ to other people, even if they have the same symptoms that you have. It may harm them. </p>   <p>This Medication Guide summarizes the most important information about PRISTIQ. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about PRISTIQ that is written for healthcare professionals. </p>   <p>For more information, go to www.pristiq.com or call 1-888-PRISTIQ (774-7847). </p>   <p> <span class="Bold">What are the ingredients in PRISTIQ?</span> </p>   <p> <span class="Bold">Active ingredient:</span> desvenlafaxine </p>   <p> <span class="Bold">Inactive ingredients:</span> For the 25 mg tablet, hypromellose, microcrystalline cellulose, talc, magnesium stearate, a film coating which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxides.</p>   <p>For the 50 mg tablet, hypromellose, microcrystalline cellulose, talc, magnesium stearate and film coating, which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxides.</p>   <p>For the 100 mg tablet, hypromellose, microcrystalline cellulose, talc, magnesium stearate, a film coating which consists of polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, iron oxide and FD&amp;C yellow #6. </p>   <p>This Medication Guide has been approved by the U.S. Food and Drug Administration. </p>   <div class="Figure">    <a name="id3173"></a>   <img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=pristiq%2D07copy%2Ejpg" alt="Logo 2" />  </div>   <p>LAB-0539-7</p>   <p>August 2014</p>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">Package/Label Display Panel</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_f846a6b5-f4b3-41b0-a0af-59a597052aee"></a>  <a name="section-18"></a>   <p></p>    <p class="First">PRISTIQ&reg;</p>   <p>(desvenlafaxine)</p>   <p>Extended-Release Tablets</p>   <p>50 mg*</p>   <p>Contains Approximately 2700 Tablets</p>   <div class="Figure">    <a name="id-231461411"></a>   <img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=image%2D02%2Ejpg" alt="bottle label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">Package/Label Display Panel</a> <div class="Section toggle-content closed" data-sectioncode="51945-4">   <a name="ID_a866da25-8dbb-4ada-a15e-d167feca406b"></a>  <a name="section-19"></a>   <p></p>    <p class="First">Pristiq&reg;</p>   <p>(desvenlafaxine)</p>   <p>Extended-Release Tablets</p>   <p>100 mg*</p>   <p>Contains Approximately 2520 Tablets</p>   <div class="Figure">    <a name="id-1405908945"></a>   <img src="image.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35&name=image%2D03%2Ejpg" alt="bottle label" />  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li><li><a href="#">INGREDIENTS AND APPEARANCE</a> <div class="DataElementsTables toggle-content">   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>PRISTIQ&nbsp; EXTENDED-RELEASE</strong> <br /> <span class="contentTableReg">desvenlafaxine succinate tablet, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:55154-4230(NDC:<a href="dailymed/search.cfm?searchdb=ndc&amp;query=0008-1211">0008-1211</a>)</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>DESVENLAFAXINE SUCCINATE</strong> (UNII: ZB22ENF0XR) (DESVENLAFAXINE - UNII:NG99554ANW)</td>          <td class="formItem">DESVENLAFAXINE</td>          <td class="formItem">50&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>HYPROMELLOSE 2208 (15000 MPA.S)</strong> (UNII: Z78RG6M2N2)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>TALC</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>AMMONIUM LAURETH-5 SULFATE</strong> (UNII: 43ZIH89I48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>POLYVINYL ALCOHOL</strong> (UNII: 532B59J990)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">PINK (LIGHT PINK)</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">SQUARE (SQUARE PYRAMID)</td>          <td class="formLabel">Size</td>          <td class="formItem">8mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">W;50</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:55154-4230-8</td>          <td class="formItem">2700 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>          <tr class="formTableRow">           <th class="formItem" scope="row">2</th>          <td class="formItem">NDC:55154-4230-2</td>          <td class="formItem">1350 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA021992</td>          <td class="formItem">05/01/2008</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table width="100%" cellpadding="3" cellspacing="0" class="contentTablePetite">     <tbody>      <tr>       <td class="contentTableTitle"><strong>PRISTIQ&nbsp; EXTENDED-RELEASE</strong> <br /> <span class="contentTableReg">desvenlafaxine succinate tablet, extended release</span></td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Information</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Product Type</td>          <td class="formItem">HUMAN PRESCRIPTION DRUG</td>          <td class="formLabel">Item Code (Source)</td>          <td class="formItem">NDC:55154-4235(NDC:<a href="dailymed/search.cfm?searchdb=ndc&amp;query=0008-1222">0008-1222</a>)</td>          </tr>          <tr class="formTableRow">           <td class="formLabel" width="30%">Route of Administration</td>          <td class="formItem">ORAL</td>          <td class="formLabel" width="30%">DEA Schedule</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Basis of Strength</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>DESVENLAFAXINE SUCCINATE</strong> (UNII: ZB22ENF0XR) (DESVENLAFAXINE - UNII:NG99554ANW)</td>          <td class="formItem">DESVENLAFAXINE</td>          <td class="formItem">100&nbsp;mg</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>          </tr>          <tr>           <th scope="col" class="formTitle">Ingredient Name</th>          <th scope="col" class="formTitle">Strength</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>HYPROMELLOSE 2208 (15000 MPA.S)</strong> (UNII: Z78RG6M2N2)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong> (UNII: OP1R32D61U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>TALC</strong> (UNII: 7SEV7J4R1U)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII: 70097M6I30)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>AMMONIUM LAURETH-5 SULFATE</strong> (UNII: 43ZIH89I48)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII: 15FIX9V2JP)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE RED</strong> (UNII: 1K09F3G675)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRow">           <td class="formItem"><strong>POLYVINYL ALCOHOL</strong> (UNII: 532B59J990)</td>          <td class="formItem">&nbsp;</td>          </tr>          <tr class="formTableRowAlt">           <td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII: EX438O2MRT)</td>          <td class="formItem">&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="4">Product Characteristics</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Color</td>          <td class="formItem">ORANGE (Reddish-orange))</td>          <td class="formLabel">Score</td>          <td class="formItem">no score</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Shape</td>          <td class="formItem">SQUARE (SQUARE PYRAMID)</td>          <td class="formLabel">Size</td>          <td class="formItem">9mm</td>          </tr>          <tr class="formTableRowAlt">           <td class="formLabel">Flavor</td>          <td class="formItem"></td>          <td class="formLabel">Imprint Code</td>          <td class="formItem">W;100</td>          </tr>          <tr class="formTableRow">           <td class="formLabel">Contains</td>          <td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td>        <table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingTitle" colspan="5">Packaging</td>          </tr>          <tr>           <th class="formTitle" width="1" scope="col">#</th>          <th class="formTitle" scope="col">Item Code</th>          <th class="formTitle" scope="col">Package Description</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <th class="formItem" scope="row">1</th>          <td class="formItem">NDC:55154-4235-8</td>          <td class="formItem">2520 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product</td>          <td class="formItem"></td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>      <tr>       <td></td>      </tr>      <tr>       <td class="normalizer">        <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">         <tbody>         <tr>           <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td>          </tr>          <tr>           <th class="formTitle" scope="col">Marketing Category</th>          <th class="formTitle" scope="col">Application Number or Monograph Citation</th>          <th class="formTitle" scope="col">Marketing Start Date</th>          <th class="formTitle" scope="col">Marketing End Date</th>          </tr>          <tr class="formTableRowAlt">           <td class="formItem">NDA</td>          <td class="formItem">NDA021992</td>          <td class="formItem">05/01/2008</td>          <td class="formItem"></td>          </tr>         </tbody>       </table> </td>      </tr>     </tbody>    </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Cardinal Health (188557102) </td>      </tr>     </tbody>   </table>  </div>   <div class="scrollingtable">   <table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%">     <tbody>     <tr>       <td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td>      </tr>      <tr>       <th class="formTitle" scope="col">Name</th>      <th class="formTitle" scope="col">Address</th>      <th class="formTitle" scope="col">ID/FEI</th>      <th class="formTitle" scope="col">Business Operations</th>      </tr>      <tr class="formTableRowAlt">       <td class="formItem">Cardinal Health</td>      <td class="formItem"></td>      <td class="formItem">188557102</td>      <td class="formItem">REPACK(55154-4230, 55154-4235)</td>      </tr>     </tbody>   </table>  </div>   <span class="close-toggle show-js"><a href="#">Close</a></span> </div></li>                                            </ul>                                        <div class="control-nav">                                            <a class="open-all" href="#">View All Sections</a><a class="close-all" href="#">Close All Sections</a>                                        </div>                                        </div>                                    </div>                        </article>                       <div class="articlefooternav">                       <h2>Find additional resources</h2> <strong>(also available in the <a href="#leftmenu">left menu</a>)</strong>                                              <h3>Safety</h3>                       <p>                                                            <a href="#boxedwarning" target="_blank">Boxed Warnings</a>,                                                                                                                     <a href="/www.accessdata.fda.gov/scripts/medwatch/ " target="_blank">Report Adverse Events</a>,                                 <a href="http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety Recalls</a>,                                 <a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22DESVENLAFAXINE%22+%29" target="_blank">Presence in Breast Milk</a>                                                   </p>                       <h3>Related Resources</h3>                       <p>                                                                                          <a href="http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&query=DESVENLAFAXINE" target="_blank">Medline Plus</a>,                                                       <a href="/www.clinicaltrials.gov/ct/search?submit=Search&term=DESVENLAFAXINE" target="_blank">Clinical Trials</a>,                            <a href="#pubmed-menu" id="pubmed-bottom">PubMed</a>,                            <a href="http://www.drugbank.ca/search?utf8=%E2%9C%93&query=DESVENLAFAXINE+SUCCINATE&search_type=drugs&button=" target="_blank">Biochemical Data Summary</a>                                                  </p>                       <h3>More Info on this Drug</h3>                       <p>                            <a href="#modal-label-archives" class="modal-open">View Label Archives</a>,                             <a href="#modal-rx-norm" class="modal-open">RxNorm</a>,                             <a href="#modal-label-rss" class="modal-open">Get Label RSS Feed</a>                        </p>                    </div>                </div>                                <div class="divider"></div>            </div>        </div>        <!-- Label Archives Modal --><div class="mfp-hide modal" id="modal-label-archives">        <div class="modal-wrapper">        <header><h2>View Label Archives for this drug</h2></header>        <div class="top">        							    	    																																			    																	    	    	                             		       	                                                                                                           <h3 class="long-title">PRISTIQ EXTENDED-RELEASE- desvenlafaxine succinate tablet, extended release <br></h3>            <h4>Number of versions: 10</h4>        </div>        <div class="modal-content">                <table class="modal">                    <tbody><tr>                        <th>Published Date</th>                        <th>Version</th>                               <th>Files</th>                    </tr>                                        <tr>                        <td>May 20, 2015</td>                        <td>							                                10                             							(current)                         </td>                              <td>                        								                                                            <a class="view-link" href="dailymed/drugInfo.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" title="View this Label">view</a><span class="sep"> | </span>                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=175278">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Oct 29, 2014</td>                        <td>							                                9                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=155779">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jul 23, 2014</td>                        <td>							                                8                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=146004">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>May 14, 2014</td>                        <td>							                                7                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=139735">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jan 14, 2014</td>                        <td>							                                6                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=129125">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Nov 14, 2013</td>                        <td>							                                5                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=124115">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Apr 1, 2013</td>                        <td>							                                4                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=104040">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Aug 3, 2012</td>                        <td>							                                3                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=84684">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Jun 13, 2012</td>                        <td>							                                2                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=81195">download</a>                                                    </td>                    </tr>                                        <tr>                        <td>Feb 11, 2011</td>                        <td>							                                1                             							                        </td>                              <td>                        								                                                                                          <a class="download-link" href="dailymed/getArchivalFile.cfm?archive_id=49164">download</a>                                                    </td>                    </tr>                                    </tbody></table>        </div>        </div></div>        <!-- RxNorm Modal --><div class="mfp-hide modal" id="modal-rx-norm">        <div class="modal-wrapper">        <header><h2>RxNorm</h2></header>        <div class="top">            <h3 class="long-title">PRISTIQ EXTENDED-RELEASE- desvenlafaxine succinate tablet, extended release <br></h3>        </div>        <div class="modal-content">        							    	    																																			    																	    	    	                             		       	                                                                                               			                            <table class="modal">                    <tbody><tr>                        <th></th>                        <th>RxCUI</th>                               <th>RxNorm NAME</th>                        <th>RxTTY</th>                    </tr>                                                                                                    <tr class="psn-rxtty">                                                                    <td>1</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790264">790264</a></td>                              <td>desvenlafaxine 100 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>2</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790264">790264</a></td>                              <td>24 HR Desvenlafaxine 100 MG Extended Release Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>3</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790264">790264</a></td>                              <td>desvenlafaxine 100 MG (as desvenlafaxine fumarate 150.9 MG) 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>4</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790264">790264</a></td>                              <td>desvenlafaxine 100 MG (as desvenlavaxine succinate 152 MG) 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>5</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790264">790264</a></td>                              <td>desvenlafaxine 100 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>6</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790267">790267</a></td>                              <td>Pristiq 100 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>7</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790267">790267</a></td>                              <td>24 HR Desvenlafaxine 100 MG Extended Release Oral Tablet [Pristiq]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>8</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790267">790267</a></td>                              <td>24 HR Pristiq 100 MG Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>9</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790267">790267</a></td>                              <td>Pristiq 100 MG (desvenlafaxine succinate 152 MG) 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>10</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790288">790288</a></td>                              <td>desvenlafaxine 50 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>11</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790288">790288</a></td>                              <td>24 HR Desvenlafaxine 50 MG Extended Release Oral Tablet</td>                        <td>SCD</td>                    </tr>                   	                                                    <tr>                                                                    <td>12</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790288">790288</a></td>                              <td>desvenlafaxine 50 MG (as desvenlavaxine fumarate 75.45 MG) 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>13</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790288">790288</a></td>                              <td>desvenlafaxine 50 MG (as desvenlavaxine succinate 76 MG) 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>14</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790288">790288</a></td>                              <td>desvenlafaxine 50 MG 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                                                <tr class="psn-rxtty">                                                                    <td>15</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790290">790290</a></td>                              <td>Pristiq 50 MG 24HR Extended Release Oral Tablet</td>                        <td>PSN</td>                    </tr>                   	                                                    <tr>                                                                    <td>16</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790290">790290</a></td>                              <td>24 HR Desvenlafaxine 50 MG Extended Release Oral Tablet [Pristiq]</td>                        <td>SBD</td>                    </tr>                   	                                                    <tr>                                                                    <td>17</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790290">790290</a></td>                              <td>24 HR Pristiq 50 MG Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                                                    <tr>                                                                    <td>18</td>                        <td><a href="dailymed/search.cfm?searchdb=rxcui&query=790290">790290</a></td>                              <td>Pristiq 50 MG (desvenlafaxine succinate 76 MG) 24 HR Extended Release Oral Tablet</td>                        <td>SY</td>                    </tr>                   	                </tbody></table>                    </div>        </div></div><!-- Label RSS Modal --><div class="mfp-hide modal" id="modal-label-rss">        <header><h2>Get Label RSS Feed for this Drug</h2></header>        <div class="top">            <h3 class="long-title">PRISTIQ EXTENDED-RELEASE- desvenlafaxine succinate tablet, extended release <br></h3>        </div>        <div class="modal-content">            <h4>To receive this label RSS feed</h4>            <p>Copy the URL below and paste it into your RSS Reader application.			<p><a href="https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35" target="_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35</a></p>            <h4>To receive all DailyMed Updates for the last seven days</h4>            <p>Copy the URL below and paste it into your RSS Reader application.</p>            <p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target="_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>            <h4>What will I get with the DailyMed RSS feed?</h4>            <p>DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.</p>            <p>DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.</p>            <h4>How to discontinue the RSS feed</h4>            <p>If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.</p>            <a href="dailymed/rss-updates.cfm" class="rss-icon"></a> <a href="dailymed/rss-updates.cfm">More about getting RSS News & Updates from DailyMed</a>        </div></div>    <!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div><div class="hide-on-mobile"></div>    <div class="mobilenav no-js">        <ul>            <li><a href="dailymed/index.cfm">Home</a></li>            <li>News                <ul>                    <li><a href="dailymed/dailymed-announcements.cfm">DailyMed Announcements</a></li>                    <li><a href="dailymed/rss-updates.cfm">Get RSS News &amp; Updates</a></li>                </ul>            </li>            <li>Search                <ul>                    <li><a href="dailymed/advanced-search.cfm">Advanced Search</a></li>                    	                    <li><a href="dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>	                    <li><a href="dailymed/archives/index.cfm">Labels Archives</a></li>                                                            <li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID Tool</a></li>                </ul>            </li>                            <li><a href="dailymed/fda-drug-guidance.cfm">FDA Guidances &amp; Information</a></li>                <li>NLM SPL Resources                    <ul>                        <li><a href="dailymed/spl-resources.cfm">Download Data</a>                            <ul>                                <li><a href="dailymed/spl-resources-all-drug-labels.cfm">All Drug Labels</a></li>                                <li><a href="dailymed/spl-resources-all-indexing-files.cfm">All Index Files</a></li>                                <li><a href="dailymed/spl-resources-all-mapping-files.cfm">All Mapping Files</a></li>                            </ul>                        </li>                        <li><a href="dailymed/splimage-guidelines.cfm">SPL Image Guidelines</a></li>                        <li><a href="dailymed/spl-resources-presentations-articles.cfm">Presentations &amp; Articles</a></li>                    </ul>                </li>                <li>Application Development Support                    <ul>                        <li><a href="dailymed/app-support.cfm">Resources</a>                            <ul>                                <li><a href="dailymed/app-support-web-services.cfm">Web Services</a></li>                                <li><a href="dailymed/app-support-mapping-files.cfm">Mapping Files</a></li>                            </ul>                        </li>                    </ul>                </li>                        <li><a href="dailymed/help.cfm">Help</a></li>                                </ul>    </div>    <footer class="mainFooter">        <div class="container">            <div class="three columns">             <div class="nihnlmlogoprint"><img src="/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>                <a href="/www.nlm.nih.gov/" class="logo" title="National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png" width="109" height="37" alt="National Library of Medicine | National Institutes of Health" title="National Library of Medicine | National Institutes of Health" /></a>            </div>                        <div id="share" class="thirteen columns">                <div class="footer-links">                    <ul class="primary">                        <li><a href="dailymed/about-dailymed.cfm" title="About DailyMed">About DailyMed</a><span>|</span></li>                        <li><a href="dailymed/contact-us.cfm" title="Contact Us">Contact Us</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/copyright.html" title="Copyright" target="_blank" rel="bookmark">Copyright</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/privacy.html" title="Privacy" target="_blank" rel="bookmark">Privacy</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/accessibility.html" title="Web Accessibility" target="_blank" rel="bookmark">Web Accessibility</a><span>|</span></li>                        <li><a href="/www.hon.ch/HONcode/Conduct.html?HONConduct393117" target="_blank" title="HONCode Certification">DailyMed is HONCode Certified</a></li>                    </ul>                    <ul class="secondary">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">National Institutes of Health</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">U.S. National Library of Medicine</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <ul class="secondary mobile">                        <li><a href="http://www.nih.gov/" title="National Institutes of Health" target="_blank" rel="bookmark">NIH</a><span>|</span></li>                        <li><a href="/www.nlm.nih.gov/" title="U.S. National Library of Medicine" target="_blank" rel="bookmark">NLM</a><span>|</span></li>                        <li><a href="http://www.hhs.gov/" title="Health &amp; Human Services" target="_blank" rel="bookmark">Health &amp; Human Services</a></li>                    </ul>                    <div class="social">                        Share                         <!-- AddThis Button BEGIN -->                        <noscript>: JavaScript needed for Sharing tools</noscript>                        <div class="addthis_toolbox addthis_default_style addthis_16x16_style">							                                                            	                                	            			        	                                                            <a class="email-share" href="mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0APRISTIQ%20EXTENDED%2DRELEASE%2D%20Desvenlafaxine%20Succinate%20Tablet%2C%20Extended%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3Da9ff32c4%2D3bcf%2D4e51%2Dae8c%2D81ff0191ec35%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E" title="Share by Email"></a>                            <a class="addthis_button_facebook"></a>                            <a class="addthis_button_twitter"></a>                            <a class="at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share" href="/www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed" target="_blank" style="width: 16px; height: 16px">                                <span style="left: -9999px; position: absolute;">Bookmark &amp; Share</span>                                <img style="width:17px; margin-top: -2px;" src="/dailymed/images/addthis-image.jpg" alt="Bookmark &amp; Share">                            </a>                        </div>                                                <!-- AddThis Button END -->                    </div>                                    </div>            </div>        </div>                <div class="divider"></div>    </footer>    <div class="divider"></div></div><div class="to-top"></div><!-- this div is only for jQuery --><div class="search-results">    <div class="filter-drop"></div></div><div class="webview"></div> <div class="hide-on-mobile"></div><!-- START OF SmartSource Data Collector TAG --><!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. --><!-- Version: 9.4.0 --><!-- Tag Builder Version: 3.3  --><!-- Created: 1/25/2012 11:57:33 PM --><script type="text/javascript" src="/dailymed/scripts/webtrends.min.js"></script><!-- ----------------------------------------------------------------------------------- --><!-- Warning: The two script blocks below must remain inline. Moving them to an external --><!-- JavaScript include file can cause serious problems with cross-domain tracking.      --><!-- ----------------------------------------------------------------------------------- --><script type="text/javascript">//<![CDATA[var _tag=new WebTrends();_tag.dcsGetId();//]]></script><script type="text/javascript">//<![CDATA[_tag.dcsCustom=function(){// Add custom parameters here.//_tag.DCSext.param_name=param_value;_tag.DCSext.dcsid=_tag.dcsid}_tag.trackAllEvents=true;_tag.dcsCollect();//]]></script><noscript><div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src="//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"/></div></noscript><!-- END OF SmartSource Data Collector TAG --><script type="text/javascript">    setTimeout(function(){var a=document.createElement("script");    var b=document.getElementsByTagName("script")[0];    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);</script><script type="text/javascript">    function getParameterByName(name) {        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),            results = regex.exec(location.search);        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));    }    /* Tracking label type on search pages */    function CE_READY() {        if(!getParameterByName('labeltype')){           CE2.set(1, "No Label Type");        }        else{            var labeltype = getParameterByName('labeltype');            if(labeltype == 'all'){                CE2.set(1, "All");            }            else if(labeltype == 'human'){                CE2.set(1, "Human");            }            else if(labeltype == 'animal'){                CE2.set(1, "Animal");            }            else{                CE2.set(1, "Unknown");            }        }    }</script>                    <!-- DAP Universal Analytics -->    <script language="javascript" id="_fed_an_ua_tag" src="/dailymed/scripts/Universal-Federated-Analytics-Min.2.0.js?agency=HHS&subagency=NIH&enhlink=true&dclink=true"></script>    <script src="/dailymed/scripts/preview-text.min.js"></script></body></html>    